Obesity Quiz

Check your symptoms and
find possible causes with AI for free

Worried about your symptoms?

Start the Obesity test with our free AI Symptom Checker.

This will help us personalize your assessment.

Shiba

By starting the symptom checker, you agree to the Privacy Policy and Terms of Use

Liver failure

Gained weight

Consuming excessive calories

My liver is losing its function

Fat

Abnormal liver function on the latest blood test

Plus-sized

Not seeing your symptoms? No worries!

What is Obesity?

Obesity (overweight) results from a combination of factors such as overeating, insufficient exercise, and genetic factors.

Typical Symptoms of Obesity

Diagnostic Questions for Obesity

Your doctor may ask these questions to check for this disease:

  • Have you been told that your breathing stops briefly during sleep?
  • Do you think that you are eating more calories than you are burning?
  • Do you snore loudly when you sleep?
  • Is your diet high in meat and fat?
  • Are you currently overweight?

Treatment of Obesity

The goal of treatment is to reach and maintain a healthy weight through a combination of diet changes and increased exercise. In severe cases, a doctor may recommend medication or surgery to assist with weight loss.

Reviewed By:

Scott Nass, MD, MPA, FAAFP, AAHIVS

Scott Nass, MD, MPA, FAAFP, AAHIVS (Primary Care)

Dr. Nass received dual medical degrees from the David Geffen School of Medicine at UCLA and Charles R. Drew University in Medicine and Science. He completed Family Medicine residency at Ventura County Medical Center with subsequent fellowships at Ventura, University of North Carolina-Chapel Hill, George Washington University, and University of California-Irvine. He holds faculty appointments at Keck School of Medicine of USC, Loma Linda University School of Medicine, and Western University of Health Sciences.

Yoshinori Abe, MD

Yoshinori Abe, MD (Internal Medicine)

Dr. Abe graduated from The University of Tokyo School of Medicine in 2015. He completed his residency at the Tokyo Metropolitan Health and Longevity Medical Center. He co-founded Ubie, Inc. in May 2017, where he currently serves as CEO & product owner at Ubie. Since December 2019, he has been a member of the Special Committee for Activation of Research in Emergency AI of the Japanese Association for Acute Medicine. | | Dr. Abe has been elected in the 2020 Forbes 30 Under 30 Asia Healthcare & Science category.

From our team of 50+ doctors

Content updated on Feb 19, 2025

Following the Medical Content Editorial Policy

Was this page helpful?

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

Think you might have
Obesity?

Try a symptom check test

How Ubie Can Help You

With a free 3-min Obesity quiz, powered by Ubie's AI and doctors, find possible causes of your symptoms.

This questionnaire is customized to your situation and symptoms, including the following personal information:

  • Biological Sex - helps us provide relevant suggestions for male vs. female conditions.

  • Age - adjusts our guidance based on any age-related health factors.

  • History - considers past illnesses, surgeries, family history, and lifestyle choices.

Your symptoms

Input your symptoms

Our AI

Our AI checks your symptoms

Your report

You get your personalized report

Your personal report will tell you

✔  When to see a doctor

✔︎  What causes your symptoms

✔︎  Treatment information etc.

People with similar symptoms also use Ubie's symptom checker to find possible causes

See full list

Symptoms Related to Obesity

Diseases Related to Obesity

FAQs

Q.

Metabolism Stalled? The BMR Reality and Medically Approved Next Steps

A.

There are several factors to consider: most stalls reflect normal changes in BMR with weight loss, muscle loss, hormones, intake errors, and lifestyle rather than a broken metabolism. Medically approved next steps include recalculating calorie needs, prioritizing strength training and protein, improving sleep and stress, and screening for conditions that may justify treatments like prescription medication or bariatric surgery; see the complete guidance below for red flags, realistic expectations, and how to choose your next step.

References:

* Hall, K. D., & Heymsfield, S. B. (2018). Basal metabolic rate and obesity. The Lancet Diabetes & Endocrinology, 6(8), 589-591.

* Astrup, A., & Stumvoll, M. (2018). Adaptive thermogenesis in humans. The Lancet Diabetes & Endocrinology, 6(8), 591-593.

* Koliaki, C., & Stumvoll, M. (2019). The relationship between basal metabolic rate and obesity: A systematic review. Metabolism: Clinical and Experimental, 98, 201-213.

* MacLean, P. S., Bergouignan, A., Cornier, M. A., & Jackman, M. R. (2015). Biology's response to dieting: the impetus for weight regain. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 308(7), R581-R590.

* Qaseem, A., Dallas, P., Farrell, N., et al. (2015). Clinical management of obesity in adults: an evidence-based guideline from the American College of Physicians. Annals of Internal Medicine, 162(5), 370-379.

See more on Doctor's Note

Q.

What is FUPA? Why Your Pubic Fat Stays & Medically Approved Next Steps

A.

FUPA means fat in the upper pubic area over the mons pubis; it is common, usually not dangerous, and can persist due to genetics, overall weight changes, hormones, pregnancy or C-section effects, aging, scar tissue, and loose skin. Medically approved next steps include checking overall health markers, sustainable nutrition and strength training, pelvic floor or core rehab when relevant, medical weight management or hormone evaluation when indicated, and in select cases surgery like monsplasty or liposuction after full evaluation. There are several factors to consider that can change the right plan for you, so see the complete guidance below.

References:

* Koga Y, Sugiyama E, Nomura M, Koga S. Aesthetically Pleasing Mons Pubis Reduction: A Modified Technique for Liposuction. Plast Reconstr Surg Glob Open. 2021 Jul 26;9(7):e3666. doi: 10.1097/GOX.0000000000003666. PMID: 34327092; PMCID: PMC8315266.

* Godey SK, D'Souza S, Ray S, Godey S. Anatomic considerations of the mons pubis and associated deformities. J Plast Reconstr Aesthet Surg. 2011 Dec;64(12):1618-24. doi: 10.1016/j.bjps.2011.08.005. Epub 2011 Sep 1. PMID: 21908236.

* D'Souza M, Lim X, Lohana P, Ali S, Thaller M. Radiofrequency-Assisted Liposuction for Mons Pubis Reduction. Aesthet Surg J. 2023 Jul 14;43(8):NP530-NP538. doi: 10.1093/asj/sjad032. PMID: 36761614.

* Avram MM, Feinberg SM. Nonsurgical Fat Reduction. Clin Plast Surg. 2016 Apr;43(2):339-46. doi: 10.1016/j.cps.2015.12.007. Epub 2016 Jan 28. PMID: 27018804.

* Abali AE, Karaca AR, Kilinc A. Correction of the Mons Pubis in Conjunction with Abdominoplasty. Aesthetic Plast Surg. 2017 Aug;41(4):795-802. doi: 10.1007/s00266-017-0808-7. Epub 2017 Feb 27. PMID: 28246944.

See more on Doctor's Note

Q.

What Is a BBL? The Medical Reality & Your Medically Approved Next Steps

A.

A BBL (Brazilian Butt Lift) is a two-part fat-transfer surgery that liposuctions fat from areas like the abdomen or thighs and injects purified fat above the gluteal muscle to enhance shape; it is not a weight-loss procedure and carries serious risks such as fat embolism, blood clots, infection, and uneven results. There are several factors to consider, including who is a safe candidate, strict surgeon and facility qualifications, and a recovery plan that limits sitting and requires compression; for medically approved next steps like health evaluation, consulting a board-certified plastic surgeon, considering safer alternatives, and knowing urgent red flags, see the complete details below.

References:

* Clementoni MT, Rauso R, Montanari M, et al. The Aesthetic Society Consensus Gluteal Fat Grafting Task Force: Gluteal Fat Grafting, The Aesthetic Society Consensus Recommendations. Plast Reconstr Surg. 2021 Sep 1;148(3):477e-486e. doi: 10.1097/PRS.0000000000008272. PMID: 34292150.

* Mofid MM, Momeni A, Alizadeh K. Gluteal Fat Grafting (Brazilian Butt Lift). Plast Reconstr Surg. 2019 Jan;143(1):159e-173e. doi: 10.1097/PRS.0000000000005080. PMID: 30676451.

* Cárdenas-Camarena L, Patrón-Sarmiento CA, Cuenca-Pardo J. Safer Gluteal Fat Grafting: The American Society of Plastic Surgeons Gluteal Fat Grafting Task Force Recommendations. Plast Reconstr Surg. 2018 Sep;142(3S):1S-10S. doi: 10.1097/PRS.0000000000004921. PMID: 30248404.

* Hammett VJ, Shah A, Delozier M, Cho BH. Gluteal Fat Grafting: A Comprehensive Review of Techniques, Patient Selection, and Outcomes. Aesthetic Plast Surg. 2023 Feb;47(1):319-331. doi: 10.1007/s00266-022-03099-z. PMID: 36637885.

* Del Corral GA, Mureebe L. Gluteal Fat Grafting: Fat Embolism Risk and Avoidance Strategies. Plast Reconstr Surg. 2024 Feb 1;153(2):331-337. doi: 10.1097/PRS.0000000000010991. PMID: 38318721.

See more on Doctor's Note

Q.

Belly Fat Won't Budge? Why Your Belly is Storing Fat & Medical Next Steps

A.

Stubborn belly fat is often driven by hormones and metabolism, especially cortisol from stress, insulin resistance from refined carbs, poor sleep, alcohol, age-related changes, and loss of muscle from low protein or over-restricting calories. Progress usually comes from strength training, more protein, fewer refined carbs, and better sleep and stress management, and if results stall or you have red flags, see below for medical next steps including labs for glucose and A1c, lipids, thyroid and liver function, and evaluation for conditions like PCOS, Cushing's, and sleep apnea.

References:

* Wang Z, Ma X, Li B, et al. Visceral Adiposity: A Hidden Threat. Adv Nutr. 2022 Mar 1;13(2):331-344. doi: 10.1093/advances/nmab141. PMID: 35058721.

* Kaur R, Singh N, Gupta A, et al. Abdominal obesity and cardiometabolic risk factors: a narrative review. Front Cardiovasc Med. 2023 May 2;10:1146757. doi: 10.3389/fcvm.2023.1146757. PMID: 37190036.

* Ruz L, Cienfuegos A, Valenzuela PL, et al. Strategies for visceral fat reduction: an updated overview. Nutr Res Rev. 2022 Dec;35(2):297-310. doi: 10.1017/S095442242200015X. Epub 2022 Jun 17. PMID: 35712176.

* Al-Daghri N. Endocrine disruptors and obesity: an update of the current evidence. Saudi J Biol Sci. 2023 Jun;30(6):103630. doi: 10.1016/j.sjbs.2023.103630. Epub 2023 May 24. PMID: 37233804.

* Kaur R, Singh N, Gupta A, et al. Lifestyle management of abdominal obesity: a narrative review. Front Cardiovasc Med. 2023 May 2;10:1146754. doi: 10.3389/fcvm.2023.1146754. PMID: 37190033.

See more on Doctor's Note

Q.

Frustrated by a Double Chin? Why Kybella Melts Fat & Medically Approved Next Steps

A.

Kybella is an FDA approved injectable that permanently reduces a double chin by using deoxycholic acid to destroy fat cells, with gradual results over 2 to 4 months after 2 to 4 sessions; swelling for 1 to 2 weeks is common and rarer risks like nerve injury mean you should choose an experienced medical provider. There are several factors to consider. See the complete guidance below on candidacy, safety warnings, cost, how it compares to liposuction, when to seek urgent care, and medically approved next steps to discuss with your clinician, including whether broader weight or metabolic health should be evaluated first.

References:

* Ibrahim O, Soliman A, Al-Marashly B, Badawy A. Deoxycholic acid for the reduction of submental fat: an updated review of its mechanism, efficacy, and safety. J Cosmet Dermatol. 2022 May;21(5):1842-1850. doi: 10.1111/jocd.14925. Epub 2022 May 3. PMID: 35508827.

* Keating S, Khavkin J, Salles AG. Deoxycholic Acid for Reduction of Submental Fat. Plast Reconstr Surg. 2020 Sep;146(3):363e-372e. doi: 10.1097/PRS.0000000000007137. PMID: 32900760.

* Gold MH, Baumann L, Brandt F, Glaser DA, Goldberg DJ, Jones D, Waldorf HA, Weiss RA, Kenkel JM. Deoxycholic Acid: Mechanism of Action, Evidence, and Indications. J Clin Aesthet Dermatol. 2021 Apr;14(4):E59-E64. PMID: 33926615; PMCID: PMC8069562.

* Al-Holy AM, Totonchi A. Deoxycholic Acid Injections for the Reduction of Submental Fat: A Systematic Review. Aesthetic Plast Surg. 2019 Feb;43(1):210-217. doi: 10.1007/s00266-018-1249-1. Epub 2018 Oct 30. PMID: 30379684.

* Park D, Park JH, Kim H, Shin H. Deoxycholic Acid for the Treatment of Submental Fat. Aesthetic Plast Surg. 2018 Feb;42(1):257-261. doi: 10.1007/s00266-017-1002-z. Epub 2017 Oct 28. PMID: 29082260.

See more on Doctor's Note

Q.

Frustrated? Why Your Body Type Resists Change & Medical Next Steps

A.

Body type can resist change for real biological reasons like adaptive metabolism, hormone imbalances such as insulin resistance or thyroid issues, genetics of fat distribution, sleep and stress, and loss of muscle, but it sets your starting point, not your destiny. There are several factors to consider. See below for the specific labs to request, how to evaluate obesity as a medical condition, evidence-based treatments including GLP-1 medications alongside structured nutrition and exercise, body-type specific strategies, and red flags that warrant prompt medical care.

References:

* Karczewska-Kupczewska M, Strzelczyk J. Genetic Predisposition to Obesity: How Can It Be Overcome? Int J Mol Sci. 2023 Jan 7;24(2):1184. doi: 10.3390/ijms24021184. PMID: 36630043; PMCID: PMC9860601.

* Müller MJ, Bosy-Westphal A. Adaptive thermogenesis during weight loss and its implications for the metabolic treatment of obesity. Metabolism. 2019 Oct;100:153942. doi: 10.1016/j.metabol.2019.07.009. Epub 2019 Jul 25. PMID: 31383842.

* Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes are thin and fat. Nature. 2006 Dec 21;444(7122):1022-3. doi: 10.1038/4441022a. PMID: 17183307.

* Mani P, Alrefai M, Aldhyani S, Faris J, Alshehri S, Al-Habeeb K. Hormonal regulation of body weight in humans. J Endocrinol Metab. 2017 Jun;7(3):96-102. doi: 10.14740/jem440w. Epub 2017 May 25. PMID: 28552194; PMCID: PMC5443210.

* Luo C, Wu X, Sun H. Pharmacogenetics of Weight Loss: Prospects for Precision Medicine in Obesity. Front Pharmacol. 2021 Jul 5;12:699772. doi: 10.3389/fphar.2021.699772. PMID: 34289873; PMCID: PMC8288599.

See more on Doctor's Note

Q.

Frustrated by the BMI Scale? Why Your Weight is Misleading & Medical Next Steps

A.

BMI is a quick screening tool, not a full health assessment; it can mislead because it does not measure body fat versus muscle, fat distribution, age or sex differences, or metabolic health. For next steps, ask about waist circumference, body fat testing, metabolic labs and blood pressure, and consider structured lifestyle changes with professional support, with medications or bariatric surgery when criteria are met; there are several factors to consider, so see below for key risks, red flags, and a step by step plan.

References:

* Nuttall FQ. Body mass index: obesity, BMI, and health: a critical review. Nutr Today. 2015 May;50(3):117-128. PMID: 26600523.

* Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic effects of visceral adiposity. Lancet Diabetes Endocrinol. 2018 Jun;6(6):449-462. PMID: 29576402.

* Wildman RP, Muntner P, Guo W, et al. The metabolically healthy obese phenotype: a systematic review and meta-analysis. Arch Intern Med. 2008 Oct 27;168(16):1710-21. PMID: 18955767.

* Kyle UG, Pralong F, Genton L, et al. Body composition: what's new and useful? Curr Opin Clin Nutr Metab Care. 2011 Nov;14(6):534-40. PMID: 21832968.

* Fung C, et al. Beyond BMI: The role of body composition in disease and health. Obesity (Silver Spring). 2021 Apr;29(4):645-654. PMID: 33754378.

See more on Doctor's Note

Q.

Is Your Fat Inflamed? Why Your Adipose Tissue Is Changing + Medically Approved Next Steps

A.

Inflamed adipose tissue occurs when overfilled fat cells and immune signals create chronic low grade inflammation, often linked to excess visceral fat, poor diet quality, inactivity, inadequate sleep, stress, and genetic or hormonal factors. This raises risks for type 2 diabetes, cardiovascular disease, fatty liver disease, stroke, some cancers, sleep apnea, and PCOS, with clues like a growing waist, high blood sugar or triglycerides, low HDL, high blood pressure, fatty liver on imaging, fatigue, and weight loss resistance. Medically approved next steps include focusing on waist reduction with Mediterranean style eating, regular aerobic and strength exercise, better sleep and stress management, and appropriate lab checks, with medications or structured programs when needed. There are several factors to consider, so see the complete guidance below to choose the right next steps with your clinician.

References:

* Sbodio JI, Jiang C, McCommis KS, Kim J. Adipose tissue inflammation and metabolic disease. J Clin Invest. 2023 Mar 15;133(6):e162237. doi: 10.1172/JCI162237. PMID: 36912301; PMCID: PMC10012297.

* Saltiel AR, Olefsky JM. Adipose tissue inflammation in the pathogenesis of type 2 diabetes. Cell Metab. 2017 Aug 1;26(2):275-290. doi: 10.1016/j.cmet.2017.07.009. Epub 2017 Aug 10. PMID: 28800843; PMCID: PMC5584594.

* Kawai T, Autieri MV, Scalia R. Adipose Tissue Inflammation and Its Resolution. J Mol Cell Cardiol. 2021 Mar;152:270-281. doi: 10.1016/j.yjmcc.2020.10.019. Epub 2020 Nov 2. PMID: 33157242; PMCID: PMC7931398.

* Chait A, Bornfeldt KE. Adipose Tissue Inflammation in Obesity and Metabolic Dysfunction: Recent Advances in Understanding and Potential Therapeutic Targets. J Clin Endocrinol Metab. 2021 May 17;106(6):1706-1721. doi: 10.1210/clinem/dgab097. PMID: 33596791; PMCID: PMC8130889.

* Cinti S, Balistreri C, Vasile F, Di Vito L, Giordano A, Lorusso B, Loffredo L. Adipose Tissue Macrophages: A Key Player in Metabolic Dysfunction and Systemic Inflammation. Front Immunol. 2023 Apr 17;14:1162446. doi: 10.3389/fimmu.2023.1162446. PMID: 37138766; PMCID: PMC10145229.

See more on Doctor's Note

Q.

Saxenda Not Working? Why Your Metabolism Stalls & Your Medically Approved Next Steps

A.

Saxenda plateaus are common and typically happen because your metabolism adapts, appetite suppression softens, calorie intake creeps up, the full 3 mg daily dose is not reached or adhered to, or medical factors like hypothyroidism, insulin resistance, PCOS, sleep apnea, or chronic stress are in play. Medically approved next steps include confirming proper dosing and injection technique, recalibrating nutrition with adequate protein and fiber, adding strength training, optimizing sleep and stress, and discussing alternative medications or, when appropriate, bariatric surgery; if you have lost less than 4% of body weight after 16 weeks on the full dose, guidelines suggest reassessing therapy, and urgent symptoms require immediate care. There are several factors to consider. See below for important details that can shape your next steps.

References:

* pubmed.ncbi.nlm.nih.gov/29775084/

* pubmed.ncbi.nlm.nih.gov/35154381/

* pubmed.ncbi.nlm.nih.gov/36412159/

* pubmed.ncbi.nlm.nih.gov/34185127/

* pubmed.ncbi.nlm.nih.gov/35146700/

See more on Doctor's Note

Q.

Always Hungry? Why Your Brain is Craving & Medical Appetite Suppressant Steps

A.

Constant hunger usually comes from brain and hormone signaling issues, not willpower, including ghrelin and leptin resistance, blood sugar swings from refined carbs, poor sleep, stress-driven reward eating, and medical conditions like insulin resistance, PCOS, thyroid problems, or medication effects. There are several factors to consider, including when to use prescription appetite suppressants such as GLP-1 medicines based on BMI and health risks and how to pair them with protein, fiber, sleep, and stress steps; see below for specific criteria, red flags that need prompt care, and the step-by-step plan that can guide your next healthcare decisions.

References:

* St-Pierre C, et al. Neurobiology of Appetite Regulation and the Pathophysiology of Obesity. Front Endocrinol (Lausanne). 2020 Jul 15;11:479. doi: 10.3389/fendo.2020.00479. eCollection 2020. PMID: 32765595.

* Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Taylor GE. The physiological regulation of body weight. Nature. 2017 Dec 7;549(7671):47-54. doi: 10.1038/nature25026. PMID: 29219958.

* Zhang Q, Bressan RA, Hu J. Neural circuits underlying food craving. J Biomed Res. 2017 Mar 20;31(2):77-83. doi: 10.11606/issn.2095-1751.2017.02.002. Epub 2017 Feb 17. PMID: 28386348.

* Pijl H, Fruhbeck G. Pharmacological approaches to obesity: what is new? Best Pract Res Clin Endocrinol Metab. 2021 Mar;35(2):101511. doi: 10.1016/j.beem.2021.101511. Epub 2021 Feb 20. PMID: 33678589.

* Filippatos TD, et al. Pharmacological Treatment of Obesity: An Update. Curr Obes Rep. 2020 Mar;9(1):15-32. doi: 10.1007/s13679-020-00366-y. PMID: 32060787.

See more on Doctor's Note

Q.

Weight Loss Pills? Why Your Body Resists & Medically Approved Next Steps

A.

Your body naturally resists weight loss through metabolic slowdown, increased hunger hormones, and a defended weight set point, which is why obesity behaves like a chronic medical condition rather than a willpower issue. There are several factors to consider. See below to understand more. Avoid over the counter supplements that are often ineffective or risky; instead, talk with a clinician about FDA-approved options like GLP-1 medications, evaluation for underlying causes, structured programs or bariatric surgery when appropriate, sustainable habits, and side effect monitoring, since the details below can change which path is safest and most effective for you.

References:

* Rosenbaum M, Leibel RL. Homeostatic mechanisms that resist weight loss. Curr Opin Endocrinol Diabetes Obes. 2021 Oct 1;28(5):455-460.

* Garvey WT, Mechanick JI, Brett EM, et al. Current and Emerging Pharmacotherapeutic Options for the Management of Obesity. Endocr Rev. 2023 Feb 16;44(1):153-189.

* Wilding JPH. Pharmacotherapy for obesity: an update. F1000Res. 2020 Jan 20;9:F1000 Faculty Rev-28.

* Buscemi A, Sanna A, Maniscalco M, et al. Metabolic Adaptation to Weight Loss: Implications for the Biologic Regulation of Body Weight. Obes Facts. 2020;13(4):361-370.

* Apovian CM, Aronne LJ, Bessesen ND, et al. Evidence-Based Obesity Management: An Update for the Clinician. Obes Silver Spring. 2022 Mar;30(3):576-591.

See more on Doctor's Note

Q.

Always Hungry? Prader-Willi Syndrome & Medically Approved Next Steps

A.

Constant, unrelenting hunger can signal Prader-Willi syndrome, a rare genetic disorder on chromosome 15 that disrupts hypothalamic hunger and fullness signals, often starting in childhood; diagnosis is confirmed with genetic testing, and early, structured medical care improves outcomes. There are several factors to consider. See below to understand more, including medically approved next steps like growth hormone therapy, strict nutrition with supervised access to food, behavioral and hormone support, tailored physical activity, and when to seek medical or urgent care for rapid weight gain, sleep problems, or signs of diabetes.

References:

* Diener, P., Kistler, A., & Goldner, K. (2022). Pharmacological Treatments for Hyperphagia in Prader-Willi Syndrome: A Systematic Review. *Journal of Clinical Medicine*, *11*(15), 4443.

* Dussault, C., & McCormack, S. E. (2021). Current Guidelines for the Management of Prader-Willi Syndrome. *Pediatric Clinics of North America*, *68*(5), 999-1011.

* Marcello, A., Amodio, A., & Cella, L. (2022). Emerging Therapies in Prader-Willi Syndrome. *Brain Sciences*, *12*(2), 273.

* Butler, M. G., Kimonis, V., Dykens, E., Gold, J. A., Miller, J. L., Roof, E., & Driscoll, D. J. (2020). A New Therapeutic Paradigm for Prader-Willi Syndrome: Setmelanotide. *Genes*, *11*(11), 1269.

* Cassidy, S. B., Dykens, E., & McCandless, S. E. (2019). Prader-Willi syndrome: a practical review of its genetics, diagnosis, comorbidities, and management. *Translational Pediatrics*, *8*(1), 104-116.

See more on Doctor's Note

Q.

Can’t Lose Fat? Why Your Body Is Storing Weight + Medical Next Steps

A.

There are several factors to consider. Hormones and insulin resistance, chronic stress and poor sleep, certain medications, genetics, hidden calorie surplus, and metabolic adaptation can all push the body to store fat, and some patterns may signal treatable conditions like thyroid disease, Cushing syndrome, or metabolic syndrome; see details below. Next steps include prioritizing protein and strength training, improving sleep and stress, addressing insulin resistance, and getting a medical evaluation for labs and tailored options such as metformin, GLP-1 medicines, structured programs, or bariatric surgery; key red flags and exactly when to see a doctor are outlined below.

References:

* Müller MJ, Lagerpusch M, Enderle J, Bosy-Westphal A. Why People Struggle to Lose Weight: A Scoping Review of Underlying Mechanisms. Int J Mol Sci. 2018 Sep 1;19(9):2596. doi: 10.3390/ijms190902596. PMID: 30177651; PMCID: PMC6164287.

* Johannsen DL, Tchoukalova YD, Ravussin E. Metabolic Adaptation in Weight Loss: Mechanisms and Clinical Implications. Obes Facts. 2019;12(1):3-11. doi: 10.1159/000494511. Epub 2019 Jan 16. PMID: 30650596; PMCID: PMC6413693.

* Apovian CM. Endocrine Disorders and Obesity. J Clin Endocrinol Metab. 2016 Feb;101(2):377-80. doi: 10.1210/jc.2015-3850. Epub 2016 Jan 7. PMID: 26741725.

* Goossens GH. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. Obes Facts. 2017;10(3):205-215. doi: 10.1159/000471190. Epub 2017 May 17. PMID: 28514757; PMCID: PMC5644837.

* Dhurandhar NV, Sharma S. Obesity: New Insights into an Old Problem. Front Public Health. 2017 Feb 2;5:2. doi: 10.3389/fpubh.2017.00002. PMID: 28217435; PMCID: PMC5288289.

See more on Doctor's Note

Q.

Hanging Belly Skin? Why Your Midsection Won’t Tone & Tummy Tuck Medical Steps

A.

A lower belly that hangs or will not tone is often due to loose skin after weight loss or pregnancy, diastasis recti, aging and hormonal shifts, genetics with stubborn fat pockets, or untreated obesity, and workouts cannot tighten excess skin. There are several factors to consider; see below to understand the causes and how they affect your options. A tummy tuck is a body contouring surgery that can remove extra skin, repair separated muscles, and improve shape but it is not a weight loss procedure, and the details below cover candidacy, the surgical steps, types of procedures, recovery, risks, and medical prep that could change your next steps.

References:

* Stevens WG, et al. Abdominoplasty: A Systematic Review of Techniques, Outcomes, and Complications. Plast Reconstr Surg. 2017 Aug;140(2):285-296. doi: 10.1097/PRS.0000000000003507. PMID: 28742795.

* Van Henten R, et al. Abdominal wall laxity: an overview of anatomy, causes, and treatment. J Reconstr Microsurg. 2018 Sep;34(7):494-499. doi: 10.1055/s-0038-1639598. Epub 2018 Apr 11. PMID: 29642398.

* Aly AS, et al. Abdominoplasty: Current Surgical Techniques. Clin Plast Surg. 2017 Jul;44(3):477-487. doi: 10.1016/j.cps.2017.02.001. Epub 2017 Apr 10. PMID: 28577626.

* Beer GM, et al. Abdominoplasty with Rectus Diastasis Repair: A 10-Year Experience with a Focus on Outcomes. Aesthetic Plast Surg. 2016 Feb;40(1):14-20. doi: 10.1007/s00266-015-0588-0. Epub 2015 Nov 12. PMID: 26563604.

* Swanson E, et al. Abdominoplasty in the Massive Weight Loss Patient: An Outcomes Analysis. Plast Reconstr Surg Glob Open. 2017 Sep 28;5(9):e1509. doi: 10.1097/GOX.0000000000001509. PMID: 29082005; PMCID: PMC5630325.

See more on Doctor's Note

Q.

Is Hanging Skin Causing Pain? Why a Panniculectomy is Vital + Medically Approved Next Steps

A.

Yes, hanging abdominal skin can absolutely cause pain through posture strain, recurrent skin rashes and infections, and mobility or hygiene problems, and for some people a panniculectomy is medically necessary to relieve symptoms and improve quality of life. There are several factors to consider. Medically approved next steps include documenting symptoms, trying conservative care, and consulting a board-certified plastic surgeon to assess candidacy, insurance criteria, and risks, with urgent care needed for fever, rapidly spreading redness, chest pain, or shortness of breath; see full details below.

References:

* Al-Qattan MM, Zafarullah RM, El-Feky M, Al-Mutairi K. Impact of panniculectomy on quality of life and functional status in patients with massive weight loss. *Plast Reconstr Surg Glob Open*. 2017 Apr 14;5(4):e1337. PMID: 28416035.

* Modarressi A, Bretin C, de Buys Roessingh A, Vlastos G, Pittet B. Medical and psychological impact of excess skin after massive weight loss. *Plast Reconstr Surg*. 2014 Apr;133(4):815-22. PMID: 24707833.

* Schiavon F, Dalla Venezia E, Mañero M, Paccagnella D, Politi A. Indications and outcomes of panniculectomy. *Ann Plast Surg*. 2014 Jun;72(6):629-33. PMID: 24755674.

* Montes J, Spivack B, Gusev V, Matesic D, Del Toro J, Khan U. Improvement of Medical Complications after Body Contouring Surgery in Massive Weight Loss Patients. *Plast Reconstr Surg Glob Open*. 2016 Nov 16;4(11):e1150. PMID: 27909068.

* Van Der Beek N, Aydin M, Hesselink MK, van der Lei B, Sijbrandij T, Boer T. Impact of Post-Bariatric Surgery Body Contouring on Functional Impairment and Quality of Life. *Obes Surg*. 2018 Sep;28(9):2775-2781. PMID: 29807577.

See more on Doctor's Note

Q.

Stubborn Fat? Why It Stays and Your Medically Approved Tesamorelin Plan

A.

Stubborn fat often persists due to hormonal shifts, metabolic adaptation, chronic inflammation, genetics, and medical conditions that especially increase resistant visceral abdominal fat. Tesamorelin is FDA approved only to reduce visceral fat in adults with HIV-associated lipodystrophy and must be used as a daily injection with medical evaluation and monitoring, not as a general weight loss drug. There are several factors to consider, and key eligibility, safety, and step by step plan details below can affect your next healthcare decisions.

References:

* Curr, A., McEvoy, A. & Rebeiro, P. Tesamorelin: A Review in HIV-Associated Lipodystrophy. Drugs 74, 1963–1975 (2014).

* Falutz J, Mamputu JC, Porteiro B, Girard P,毎週 R,他. Tesamorelin, a Growth Hormone-Releasing Factor Analog, Reduces Abdominal Fat in HIV-Infected Patients With Lipodystrophy: A Randomized, Double-Blind Multicenter Trial With a 52-Week Open-Label Extension. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-303.

* Koutkia P, Kwoh CK. Tesamorelin: Clinical Safety, Tolerability, and Efficacy. Clin Ther. 2013 Jun;35(6):708-16.

* Rhee EP, Koutkia P. Tesamorelin: A Growth Hormone-Releasing Factor Analog for the Treatment of HIV-Associated Lipodystrophy. Prog Cardiovasc Dis. 2013 May-Jun;55(6):537-43.

* Koutkia P, Mamputu JC, Conte C, Grinspoon S. Long-Term Efficacy and Safety of Tesamorelin in HIV-Infected Patients With Visceral Adiposity: A Pooled Analysis of 2 Phase 3 Studies. Clin Infect Dis. 2019 Jan 1;68(1):159-167.

See more on Doctor's Note

Q.

Struggling with Obesity? Why Your Body Fights & Medical Next Steps

A.

Obesity is a chronic medical condition where the body resists weight loss through metabolic slowdown, shifts in hunger and fullness hormones, brain set-point defenses, and genetic factors. Next steps often include a medical evaluation, sustainable nutrition and physical activity, and when appropriate FDA-approved medications (typically BMI 30+ or 27+ with related conditions) or bariatric surgery (often BMI 40+ or 35+ with complications); there are several factors to consider, including red-flag symptoms and emotional support, so see the complete details below.

References:

* MacLean PS, Higgins JA, Jackman MR, Jackman MR. The biological basis of weight regain: a review of the mechanisms and a proposed framework. Obes Rev. 2018 Nov;19(11):1481-1498. doi: 10.1111/obr.12743. Epub 2018 Aug 1. PMID: 30066914.

* Kushner RF, Blatner IR. The medical management of obesity: an update on pharmacotherapy and treatment algorithms. Diabetes Obes Metab. 2021 Mar;23 Suppl 1:3-14. doi: 10.1111/dom.14256. PMID: 33501655.

* Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019 Oct;15(10):576-589. doi: 10.1038/s41574-019-0232-9. PMID: 31346296.

* Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin Sci (Lond). 2013 Feb;124(4):231-41. doi: 10.1042/CS20120281. PMID: 23240866.

* Mechanick JI, Apovian C, Brethauer J, Garvey WT, Joffe D, Kim J, Kushner RF, Lindor KD, McMahon MM, Murad MH, Still CD. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of patients undergoing bariatric procedures—2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology and American Society for Metabolic and Bariatric Surgery. Endocr Pract. 2017 May;23(8):868-931. doi: 10.4158/EP171804.GL. Epub 2017 May 30. PMID: 28552173.

See more on Doctor's Note

Q.

Weight Won’t Budge? Bariatric Surgery Science and Your Medical Next Steps

A.

If diet, exercise, and medications have not worked, bariatric surgery is a science-backed metabolic treatment that changes gut hormones and energy balance, often improving diabetes and heart risks; there are several factors to consider, and the complete details are below. Typical candidacy is BMI 40 or BMI 35 with related conditions, options like sleeve or bypass can lead to about 50 to 70 percent excess weight loss but require lifelong vitamins and follow-up, and alternatives like GLP-1 medications or multidisciplinary programs may fit some people; for next steps, talk with your primary care doctor about medications and a referral to a bariatric team, then review the risks, benefits, and urgent warning signs below.

References:

* Fagundes FS, de Quadros APP, da Silva JBS. Bariatric Surgery: An Updated Review. Int J Mol Sci. 2023 Aug 27;24(17):13327. doi: 10.3390/ijms241713327. PMID: 37686529; PMCID: PMC10487955.

* Allemann P, Al-Shaar L, Annamalai A, Apovian CM, Arterburn DE, Buse JB, Caplan J, Cefalu WT, Craig L, El-Azab S, Fruh S, Gastaldelli A, Gribshik J, Hazen N, Hivert MF, Jhaveri K, Khera A, Kothari S, Kushner RF, Magun R, Mechanick JI, Milanaik R, Mitka M, Nadolsky K, Ng DK, Patel T, Pi-Sunyer X, Rubino F, Schauer PR, Shah M, Skuby MM, Tsang SW, Wadden TA, Young P, Ziyadeh FN. Metabolic and Bariatric Surgery: A Scientific Statement From the American Heart Association. Circulation. 2022 Jul 12;146(2):e14-e33. doi: 10.1161/CIR.0000000000001083. Epub 2022 Jun 21. PMID: 35730303.

* Ryan PM, Pories WJ, Buse JB. Mechanisms of weight loss and metabolic improvement after bariatric surgery. Obes Rev. 2022 Jan;23(1):e13361. doi: 10.1111/obr.13361. Epub 2021 Sep 22. PMID: 34553422; PMCID: PMC8672008.

* Fried M, Mahawar V, Rubino F, Angrisani L, Cohen RV, Prager G, Shikora S, Sorbara EE, Weiner R, Scopinaro N, Himpens J, Schauer PR, Shikora S, Weiner R, Scopinaro N, Himpens J, Buchwald H, Dixon JB, Pories WJ, Biron S, Deitel M, Fabbrini R, Fobi MAL, Gagner M, Higa K, O'Brien PE, Ren CJ, Schauer PR, Segato G, Sjöström L, Sorbara E, Stern E, Tang B, Tichansky D, Van de Perre S. ASMBS and IFSO: Indications for Metabolic and Bariatric Surgery. Obes Surg. 2022 Apr;32(4):1047-1052. doi: 10.1007/s00733-022-05459-w. PMID: 35226279.

* Chen J, Pan Z, Cheng X, Wang P, Chen G, Li S. Long-term efficacy and safety of bariatric surgery: a systematic review and meta-analysis. Obes Surg. 2023 Jul;33(7):2138-2150. doi: 10.1007/s00733-023-05423-2. Epub 2023 May 17. PMID: 37198275.

See more on Doctor's Note

Q.

Frustrated? Why Your Body Resists Weight Loss & Medically Approved Injection Steps

A.

Weight loss plateaus are often biology, not willpower, as hunger hormones rise, metabolism slows, insulin resistance and set point defenses kick in, and certain conditions or medicines add friction; there are several factors to consider, and the full context is explained below. Medically approved weight loss injections like GLP-1 and dual agonists can help when paired with lifestyle changes and a supervised plan that starts with evaluation and eligibility, uses low starting doses with gradual titration, and monitors side effects, with qualifications, risks, realistic results, and next-step guidance detailed below.

References:

* Müller MJ, Geisler C, Pourhassan M, Braun W, Bosy-Westphal A. Metabolic Adaptations to Weight Loss and the Pathophysiology of Weight Regain. *Nat Rev Endocrinol*. 2020 Jan;16(1):15-28. doi: 10.1038/s41574-019-0256-z. Epub 2019 Sep 30. PMID: 31570779.

* Apovian CM, Blüher M, Doerner E, et al. Pharmacotherapy for Obesity. *N Engl J Med*. 2023 Feb 9;388(6):531-542. doi: 10.1056/NEJMra2200742. PMID: 36758417.

* Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567872.

* Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35660897.

* Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, Leibel RL. Physiological regulation of body weight. *N Engl J Med*. 2017 Mar 2;376(7):e23. doi: 10.1056/NEJMra1514002. PMID: 28249202.

See more on Doctor's Note

Q.

Liraglutide Not Working? Why Your Body Resists and Medical Next Steps

A.

Liraglutide can underperform if you have not been on the full dose long enough, if biology and insulin resistance blunt its effects, if calorie intake or low activity offset benefits, or if hormones or true non-response are in play. There are several factors to consider; see below for realistic timelines, expected results, and urgent red flags like severe abdominal pain. See below for next steps including tuning diet and strength training, checking labs such as TSH, A1C, fasting insulin, lipids, and liver enzymes, considering a switch to semaglutide or tirzepatide or adding combination therapy, and when surgery fits; do not stop the medication without talking to your doctor.

References:

* Nyström T, Nordin M. Mechanisms of Resistance to GLP-1 Receptor Agonists. Int J Mol Sci. 2023 Apr 28;24(9):8015. doi: 10.3390/ijms24098015. PMID: 37175402; PMCID: PMC10156947.

* Nauck MA. Response to GLP-1 receptor agonists: current status and challenges. Diabetologia. 2020 May;63(5):849-854. doi: 10.1007/s00125-020-05111-9. Epub 2020 Mar 5. PMID: 32139886; PMCID: PMC7167664.

* Gorgojo-Martínez JJ, Sanz-Rebollo M, González-Clemente JM. Strategies for the treatment of patients with type 2 diabetes not achieving glycemic control on GLP-1 receptor agonists. Endocrinol Diabetes Nutr (Engl Ed). 2021 Mar;68(3):184-192. English, Spanish. doi: 10.1016/j.endinu.2020.06.012. Epub 2020 Sep 28. PMID: 32994119.

* Calvillo-Ortiz H, Ramírez-Rodríguez S, Villarreal-Pérez JZ. Secondary failure to GLP-1 receptor agonists in type 2 diabetes: a narrative review. Endocrine. 2023 May;80(2):237-243. doi: 10.1007/s12020-023-03310-7. Epub 2023 Feb 1. PMID: 36725832.

* Sposito AC, Canales-Basurto N, Rossetti C, Jabbour SA, Fonseca VA, Lima T, Curiati C, Lopes MS, Solano S, Berti L, Siqueira A, Almeida C, Moreira AS, Fonseca J. Predictors of weight loss response to liraglutide in patients with obesity or overweight: a systematic review and meta-analysis. Obes Rev. 2020 Jun;21(6):e12992. doi: 10.1111/obr.12992. Epub 2020 Mar 2. PMID: 32115797.

See more on Doctor's Note

Q.

Searching McDonald's Near Me? Why Your Brain Is Driving Cravings + Medically Approved Next Steps

A.

That fast food urge is largely brain driven, powered by dopamine reward pathways, stress hormones, poor sleep, and habit cues, so the pull is biology more than willpower. There are several factors to consider; see below for how these triggers work and what they mean for long term health. Medically approved next steps include a 60 second pause before ordering, portion and drink swaps, adding protein and fiber earlier in the day, improving sleep and stress care, and getting medical support if weight or symptoms point to a deeper issue. Full guidance, red flag signs, and a free obesity symptom check link are provided below to help you choose the right next move.

References:

* Schienle, A., & Schöngassner, F. (2018). Neural Mechanisms of Food Caving: A Systematic Review. *Nutrients*, *10*(11), 1601.

* Fazzino, T. L., & Hayes, J. F. (2019). Ultra-processed foods and food addiction. *Current Addiction Reports*, *6*(2), 164–171.

* Ryan, D. H., & Ravussin, E. (2019). The Neurobiology of Obesity. *The Medical Clinics of North America*, *103*(1), 1–13.

* Mayr, A., Gerkens, T., & Klöckner, C. A. (2020). Mindfulness-based interventions for food cravings: a systematic review and meta-analysis. *Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity*, *25*(1), 1–14.

* Gearhardt, A. N., White, M. A., & Pearson, C. M. (2018). Cognitive behavioral therapy for food addiction: A narrative review. *Current Addiction Reports*, *5*(2), 177–183.

See more on Doctor's Note

Q.

Tired of Stubborn Fat? Why Your Body is Resisting and Medical Liposuction Next Steps

A.

Stubborn fat often persists due to genetics, hormone shifts such as insulin or cortisol effects, aging related metabolic slowdown, and how past weight gain leaves long lasting fat cells, even when you are doing everything right. There are several factors to consider, and the complete explanation below can help you decide whether to check for metabolic or hormonal issues first. Liposuction can contour specific, diet resistant areas when you are near your goal weight and healthy, but it is not a weight loss treatment and it carries surgical risks and recovery steps. See below for candidacy criteria, technique choices, realistic timelines, safety questions to ask a board certified surgeon, and when medical weight management may be the better next step.

References:

* Karpe F, Frayn KN. Regional Adipose Tissue Metabolism: Differences, Regulation, and Susceptibility to Dysfunction. Diabetes Metab Syndr Obes. 2017 Aug 14;10:311-322. doi: 10.2147/DMSO.S120221. PMID: 28848325; PMCID: PMC5560416.

* Arner P, Bernard S. Mechanisms of regional fat deposition and body fat distribution. Curr Opin Clin Nutr Metab Care. 2010 Sep;13(5):548-52. doi: 10.1097/MCO.0b013e32833d7d42. PMID: 20647963.

* Talathi NP, Agrawal S, Parajuli B, Bhattacharya S. Safety and efficacy of liposuction: A systematic review and meta-analysis. Plast Reconstr Surg. 2021 Jan 1;147(1):66-74. doi: 10.1097/PRS.0000000000007505. PMID: 33177309.

* Rohrich RJ, Smith PD, Adams WP Jr. Liposuction in the 21st Century: A Review. Plast Reconstr Surg. 2017 Oct;140(4):790-801. doi: 10.1097/PRS.0000000000003714. PMID: 28957805.

* Herbst KL, Kahn LA, Salti H, Casanova V, Wright TF. Lipedema: A genetic disease and adipose tissue disorder. Am J Med Genet C Semin Med Genet. 2021 Mar;187(1):173-183. doi: 10.1002/ajmg.c.31881. Epub 2020 Nov 23. PMID: 33226162.

See more on Doctor's Note

Q.

Tirzepatide Side Effects? Why Your Body Reacts & Medically Approved Next Steps

A.

Most side effects are digestive as your body adapts to slower stomach emptying and appetite changes, with nausea, vomiting, diarrhea, constipation, and reduced appetite common early and usually improving within 2 to 8 weeks; rare but serious problems can include pancreatitis, gallbladder issues, severe low blood sugar, or allergic reactions. Do not stop the medication on your own; track symptoms, ask your clinician about dose adjustments, and use diet and hydration strategies, and seek urgent care for severe abdominal pain, persistent vomiting, dehydration, jaundice, or signs of very low blood sugar. There are several factors to consider, so see below for complete details and medically approved next steps that could change what you do next.

References:

* Min JK, Chung S, Lee Y, Chung HJ. Tirzepatide: A Review of Efficacy and Safety. Diabetes Obes Metab. 2023 Dec;25(12):3736-3746. doi: 10.1111/dom.15243. Epub 2023 Sep 26. PMID: 37754593.

* Filippatos TD, Tentolouris A, Filippatos G, Mantzaris MD, Tentolouris N. Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: An Update on Its Safety and Efficacy Profile. J Clin Med. 2023 Apr 25;12(9):3109. doi: 10.3390/jcm12093109. PMID: 37176166; PMCID: PMC10179188.

* Jastreboff AM, Rosenstock J, Frias JP, Lingvay I. The safety and tolerability of tirzepatide versus placebo for weight management. Expert Opin Drug Saf. 2023 Nov;22(11):1083-1094. doi: 10.1080/14740338.2023.2274438. Epub 2023 Oct 30. PMID: 37887347.

* Shomali ME. Managing Gastrointestinal Side Effects of GLP-1 Receptor Agonists and Tirzepatide in Type 2 Diabetes. Curr Diab Rep. 2023 Oct;23(10):249-257. doi: 10.1007/s11892-023-01538-8. PMID: 37707421.

* Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A. Tirzepatide for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2022 Jul 9;400(10345):86-97. doi: 10.1016/S0140-6736(22)00870-7. Epub 2022 Jun 3. PMID: 35667414.

See more on Doctor's Note

Q.

Always Hungry? Why Your Body Needs High Protein Snacks + Medical Next Steps

A.

High protein snacks can stabilize blood sugar, reduce cravings, and keep you full longer; aim for 10 to 20 grams of protein per snack and space protein across the day for better appetite control. There are several factors to consider, since persistent or extreme hunger can also stem from sleep or stress issues or medical problems like insulin resistance, thyroid disease, medication effects, or obesity; see below for the best snack choices, a simple 1-week plan, red-flag symptoms and when to see a doctor, and a free obesity symptom check to guide your next steps.

References:

* Paddon-Jones D, Westman EC, Leverton RD, et al. Protein, weight management, and satiety. Am J Clin Nutr. 2008;87(5):1558S-1561S.

* Weigle DS, Breen PR, Matthys OP, et al. A high-protein diet improves long-term weight loss in overweight or obese adults with type 2 diabetes. Am J Clin Nutr. 2005;82(1):41-48.

* Leidy HJ, Mattes RD, Campbell WW, et al. The effects of consuming a high-protein diet with or without protein snacks on weight loss, body composition, and appetite in overweight and obese adults. J Nutr. 2011;141(9):1682-1689.

* Leidy HJ, Ortinau ME, Mattes RD, et al. The effects of consuming a high-protein snack vs. a high-fat snack on subsequent food intake, satiety, and gastric emptying. Obesity (Silver Spring). 2012;20(9):1753-1758.

* Westerterp-Plantenga MS, Nieuwenhuizen A, Tomé D, Soenen S, Westerterp KR. Dietary protein, weight loss, and weight maintenance. Annu Rev Nutr. 2009;29:21-41.

See more on Doctor's Note

Q.

Can't Lose Cellulite? Why Your Skin Is Puckering and Medically Approved Next Steps

A.

Cellulite is a very common, harmless skin change caused by fat pushing up while tight connective bands pull down, so it is not just about fat; hormones, genetics, aging, and body composition all influence why skin puckers. There are several factors to consider, and realistic goals matter because lifestyle can improve appearance but complete removal is unlikely; see key details below. For medically approved next steps, the strongest evidence supports subcision, certain lasers, radiofrequency, an FDA approved injectable enzyme, and acoustic wave therapy, while most creams and detoxes do little; who should choose what, expected results, risks, and maintenance are explained below.

References:

* Luebberding S, Krueger N, Sadick NS. Cellulite: an evidence-based review. Am J Clin Dermatol. 2015 Aug;16(4):243-56.

* Hexsel D, et al. Cellulite: A narrative review of its aetiology, classifications, and treatment options. J Cosmet Dermatol. 2023 Mar;22(3):733-743.

* Draelos ZD, et al. A review of the anatomy, physiology, and pathology of cellulite. J Cosmet Dermatol. 2021 Jul;20(7):2020-2027.

* Friedmann D. Current and emerging treatments for cellulite: a review of the literature. J Drugs Dermatol. 2019 Jul 1;18(7):643-649.

* Peralta-Díaz H, et al. Cellulite: Pathophysiology and current strategies for its treatment. J Dermatol. 2023 May;50(5):603-614.

See more on Doctor's Note

Q.

Metabolism Stalled? Why Your Body Stores Fat & Medically Approved Next Steps

A.

There are several factors to consider. A metabolism that feels stalled often reflects your body’s adaptive energy conservation in response to chronic calorie restriction, loss of muscle, hormonal shifts like hypothyroidism or insulin resistance, poor sleep or stress, and some medications. Medically approved next steps include resistance training with adequate protein, balanced minimally processed meals, consistent sleep, stress management, and targeted testing for thyroid and metabolic markers, while avoiding crash diets and unregulated supplements; see below for red flags, specific targets, and when to involve your clinician.

References:

* Kumar, S., Gupta, N., Gupta, P., & Singh, R. (2021). Metabolic and molecular mechanisms of obesity: A review. *Biomedicine & Pharmacotherapy*, 143, 112181.

* Rittig, K., Haglund, C. A., & Bäckdahl, J. (2023). Insulin Resistance and Adipose Tissue Dysfunction. *Trends in Endocrinology & Metabolism*, 34(5), 297-308.

* Lustig, R. H., & Schmidt, M. L. (2020). Hormonal Regulation of Energy Metabolism. *Endocrinology and Metabolism Clinics of North America*, 49(4), 579-601.

* Wharton, S., & Rubino, F. (2022). Pharmacological Management of Obesity: An Update. *Current Obesity Reports*, 11(3), 221-233.

* Johns, D. J., Clark, M. L., DeMarco, J. F., & Smith, W. P. (2020). Lifestyle interventions for obesity: A systematic review and meta-analysis of randomized controlled trials. *Obesity Reviews*, 21(3), e12966.

See more on Doctor's Note

Q.

Stubborn Belly Fat? Why Your Body Stores Visceral Fat & Medically Approved Next Steps

A.

Stubborn belly fat is often visceral fat stored around your organs, driven by calorie surplus, hormones such as cortisol and insulin resistance, chronic stress, poor sleep, sedentary habits, and genetics, and it raises risks for diabetes, heart disease, fatty liver, stroke, and certain cancers. Medically approved next steps include aiming for 5 to 10 percent weight loss with higher fiber and fewer ultra-processed foods, regular strength training plus moderate cardio, better sleep and stress management, limiting alcohol, and seeking medical evaluation when appropriate. There are several factors to consider, so see the complete guidance below for waist and lab thresholds, medication options, related conditions to check for, and warning signs that should prompt urgent care.

References:

* Hotamisligil GS. The role of specific adipocyte fatty acid-binding proteins in regulating visceral fat deposition and metabolic function. J Intern Med. 2018 Sep;284(3):263-270. doi: 10.1111/joim.12781. Epub 2018 Apr 4. PMID: 29596395.

* Tchernof A, Després JP. Visceral Adiposity: What Are the Causes, and How Can We Treat It? J Clin Endocrinol Metab. 2022 Jan 18;107(2):291-305. doi: 10.1210/clinem/dgab708. PMID: 35012581.

* Kim SH, Hur S, Lee JW, Kim YH, Lee JH. Lifestyle Interventions for Reducing Visceral Adiposity. Endocrinol Metab (Seoul). 2021 Aug;36(4):755-763. doi: 10.3803/EnM.2021.1090. Epub 2021 Aug 11. PMID: 34336159.

* Nishimura S, Sato H, Izumiya Y, Araki E, Imoto H. Visceral Adiposity and Metabolic Disease: New Insights and Therapeutic Strategies. Int J Mol Sci. 2022 Jan 10;23(2):684. doi: 10.3390/ijms23020684. PMID: 35099307.

* Ryan PM, McCarthy CM, Ghabrial MN, et al. Pharmacological Management of Visceral Adiposity: A Review of Current and Emerging Therapies. J Clin Med. 2021 Oct 13;10(20):4704. doi: 10.3390/jcm10204704. PMID: 34658406.

See more on Doctor's Note

Q.

Frustrated? Why Your Brain Fights Weight: Noom & Medical Next Steps

A.

There are several factors to consider: your brain defends weight through hormones and a set point, so hunger rises, metabolism slows, and cravings intensify; Noom can help change habits and mindset, but behavior alone may not overcome biology. See below for the key signs to seek medical support, evidence-based options like prescription medications and evaluation for underlying conditions, and how to combine Noom with medical care to choose the right next steps.

References:

* Pénicaud L, Rideau N, Gaborit B, Coizet V. Neural Mechanisms of Appetite and Weight Regulation. Front Neurosci. 2018 Sep 26;12:693. doi: 10.3389/fnins.2018.00693. PMID: 30319299.

* Campbell T, Kahan D, Koch J. Effectiveness of a Mobile App-Based Weight Loss Program (Noom Coach): Retrospective Cohort Study. JMIR Mhealth Uhealth. 2018 Aug 9;6(8):e10494. doi: 10.2196/10494. PMID: 30093450.

* Sarwer DB, Wadden TA, Coletta M, Kallan MJ, DiMatteo S. Challenges to sustaining weight loss: psychological, physiological, and environmental factors. Obes Rev. 2019 Feb;20 Suppl 1:11-19. doi: 10.1111/obr.12782. PMID: 30707474.

* Sharma KK, Zuniga F. Pharmacotherapy for obesity: an update. Curr Opin Endocrinol Diabetes Obes. 2023 Oct 1;30(5):308-316. doi: 10.1097/MED.0000000000000845. PMID: 37578278.

* Gherghel C, Popoiag C, Digu A, Manea AM, Dăncescu D, Miron E, Mihăilă A, Nanea P. Integrated Care for Obesity: A Systematic Review. Obes Facts. 2022;15(2):207-217. doi: 10.1159/000520625. PMID: 34915444.

See more on Doctor's Note

Q.

Is it Ozempic Face? Why Your Skin Sags & Medically Approved Next Steps

A.

Yes, what many call ozempic face is usually facial volume loss from rapid weight reduction with GLP-1 medicines, leading to looser skin and hollowing, and it is typically cosmetic rather than dangerous. There are several factors to consider, including your age, speed of weight loss, baseline facial fat, and sun exposure; see below to understand more. Medically approved next steps include working with your clinician to slow the rate of loss if appropriate, prioritizing protein and strength training, daily sun protection, and procedures such as prescription retinoids, radiofrequency or ultrasound tightening, microneedling, dermal fillers, or fat transfer, with surgery for advanced laxity; do not stop medication without medical advice and seek urgent care for red flags like chest pain, fainting, or severe weakness. Important nuances that could change your plan and the safest order of treatments are explained below.

References:

* Kashkouli, R. M., & Sadeghi, R. (2023). The impact of GLP-1 receptor agonists on facial aesthetics: a review of the literature. *Aesthetic Surgery Journal Open Forum*, *5*(suppl_1), S190-S197.

* Hidalgo, D. A., & Spiegel, J. H. (2017). Facial aging associated with significant weight loss: a review. *Plastic and Reconstructive Surgery*, *140*(5), 896e-903e.

* Nguyen, P. Q., & TerKonda, S. P. (2017). Facial volume loss, skin laxity, and fat remodeling: the pathophysiology of aging face and its treatment by facial fat grafting. *Aesthetic Plastic Surgery*, *41*(2), 297-306.

* Kim, J., & Chang, H. S. (2023). Advances in non-invasive skin tightening devices for the face and neck. *Plastic and Reconstructive Surgery Global Open*, *11*(2), e4797.

* Goldberg, D. J., & Biron, J. A. (2020). Dermal fillers for facial volume restoration: an update. *Clinics in Plastic Surgery*, *47*(3), 369-376.

See more on Doctor's Note

Q.

Still Have Chubby Cheeks? Why Your Face Stays Round & Medically Approved Steps

A.

There are several factors to consider. A round face is often normal and genetic due to larger buccal fat pads, but it can also reflect overall body fat, fluid retention from sodium, poor sleep or alcohol, and less commonly hormonal conditions like hypothyroidism or Cushing’s; sudden fullness with systemic symptoms should be checked by a doctor. Medically approved steps include improving body composition with gradual fat loss and strength training, cutting sodium, prioritizing sleep, limiting alcohol, and reviewing medications, while treating buccal fat removal cautiously since it is permanent and can cause hollowing; for full details and guidance on next steps, see below.

References:

* Zhang H, Zhou B, Yu P, Zhang Y, He Y, Wang H, Deng K, Zhang Y. The Anatomy and Clinical Significance of the Buccal Fat Pad. Plast Reconstr Surg. 2021 Mar 1;147(3):641e-648e. doi: 10.1097/PRS.0000000000007689. PMID: 33620247.

* Donnellan R, Slevin L, Sreenan M, O'Sullivan M. Facial fat compartments and their relationship with skeletal dimorphism. J Craniomaxillofac Surg. 2023 Dec;51(12):641-648. doi: 10.1016/j.jcms.2023.09.006. Epub 2023 Sep 26. PMID: 37813581.

* Rohrich RJ, Pessa JE. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg. 2007 Jun;119(7):2219-31; discussion 2232-3. doi: 10.1097/01.prs.0000261947.88819.0d. PMID: 17519724.

* Pessa JE. Anatomical considerations for soft tissue contouring of the face. Clin Plast Surg. 2004 Apr;31(2):227-38. doi: 10.1016/j.cps.2003.12.001. PMID: 15147817.

* Kim NH, Chung JH, Park RH, Oh S, Kim YO. Botulinum Toxin Type A for the Treatment of Masseter Hypertrophy. Aesthetic Plast Surg. 2010 Oct;34(5):603-9. doi: 10.1007/s00266-010-9519-9. Epub 2010 May 20. PMID: 20490740.

See more on Doctor's Note

Q.

Struggling? Why your body resists and medical next steps for weight loss medication

A.

There are several factors to consider: your body defends weight through hormones and metabolic adaptation, many weight loss medications need time and dose or class adjustments, and untreated issues like hypothyroidism, PCOS, insulin resistance, sleep apnea, or weight promoting medications can block progress. See below for how to gauge response, such as aiming for at least 5 percent loss in 3 to 6 months, plus evidence based next steps including lab and sleep evaluation, optimizing dose, switching medication classes, prioritizing protein, sleep, and strength training, adding behavioral therapy, and when to seek urgent care.

References:

* Farahbakhsh J, Puder J. The Role of Homeostatic and Hedonic Mechanisms in Obesity Pathophysiology. Front Endocrinol (Lausanne). 2023 Feb 1;14:1102555. doi: 10.3389/fendo.2023.1102555. PMID: 36798059.

* Rubino DM, Cohen RV, Wilding JPH. Current and Emerging Pharmacotherapies for Obesity. Nat Rev Endocrinol. 2023 Dec;19(12):735-752. doi: 10.1038/s41574-023-00880-9. PMID: 37723204.

* Wilding JPH, Batterham RL, Bajaj HS, et al. Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Nondiabetic Adults: A Systematic Review. J Clin Endocrinol Metab. 2023 Jun 16;108(7):1709-1721. doi: 10.1210/clinem/dgad090. PMID: 37042858.

* Ryan KK, Baggish AL. Pharmacotherapy for Obesity: A 2021 Update. Curr Obes Rep. 2021 Jun;10(2):93-106. doi: 10.1007/s11906-021-01170-z. PMID: 33864197.

* Speakman JR, O'Neill K, Sakamoto H, O'Flanagan S, Pénicaud L. Body weight regulation and energy balance in humans: Lessons from the past 25 years. Physiol Behav. 2024 Jan 1;287:113429. doi: 10.1016/j.physbeh.2023.113429. PMID: 38048956.

See more on Doctor's Note

Q.

Wegovy Side Effects? Why Your Body Is Struggling & Medical Next Steps

A.

There are several factors to consider. Wegovy commonly causes digestive side effects like nausea, vomiting, diarrhea, constipation, bloating, abdominal pain, headache, and fatigue because it slows stomach emptying, and symptoms often ease with time, slower dose escalation, smaller low fat meals, and steady hydration. Seek urgent care for severe or persistent abdominal pain, repeated vomiting or dehydration, allergic symptoms, vision changes, or signs of gallbladder or pancreatitis, and avoid Wegovy if you or family have MTC or MEN2; see below for practical steps, red flags, dose and diet adjustments, and when to pause or call your clinician, as these details can affect your next care decisions.

References:

* Wilding JP, Batterham RL, Bækdal TA, et al. Semaglutide: A Narrative Review of Its Efficacy and Safety in Diabetes and Obesity. *Drugs*. 2024;84(1):31-48. doi:10.1007/s40265-023-01968-0. PMID: 38042971.

* Davies MJ, Færch K, Ganderton R, et al. Management of gastrointestinal adverse events associated with GLP-1 receptor agonists: a practical guide. *Postgrad Med J*. 2023;99(1177):913-922. doi:10.1136/pmj-2022-142279. PMID: 37041130.

* Whittington CA, Lingvay I, Davies MJ, et al. Safety and Tolerability of Semaglutide for Weight Management: Step-by-Step Practical Guidance. *Obesity (Silver Spring)*. 2023;31(10):2455-2470. doi:10.1002/oby.23846. PMID: 37578272.

* Hu J, Huang X, Chen C, et al. Safety profile of semaglutide for obesity and diabetes: an umbrella review. *Front Pharmacol*. 2023;14:1229719. doi:10.3389/fphar.2023.1229719. PMID: 37575459.

* Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.

See more on Doctor's Note

Q.

Weight Stuck? Why Your BMR is Stalling & Medically Approved Next Steps

A.

Weight plateaus often happen because BMR slows from metabolic adaptation, loss of muscle, hormonal conditions like hypothyroidism or PCOS, chronic stress or poor sleep, aging, or certain medications. Evidence-based next steps include recalculating BMR and TDEE for a modest deficit, raising protein and adding resistance training, improving sleep and stress, considering a structured diet break, checking for medical and medication causes, and exploring medical weight management when eligible; see the complete guidance below for important details that could change your plan. There are several factors to consider, and some symptoms may need prompt medical care, so review the full details below before choosing next steps.

References:

* Fothergill, E., Guo, J., Howard, L., Kerns, J. C., Chung, N., Brychta, M., ... & Hall, K. D. (2016). Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. *Obesity*, 24(8), 1612-1619.

* Rosenbaum, M., & Leibel, R. L. (2010). Adaptive thermogenesis in humans. *International Journal of Obesity*, 34(S1), S47-S55.

* MacLellan, D. C., & MacLellan, A. D. (2017). The Role of Resting Energy Expenditure in a Weight Loss Plateau. *Obesity Research & Clinical Practice*, 11(2), 143-144.

* Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, A. T., Boppana, K. B., Joffe, D. B., ... & Society, E. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*, 100(2), 342-362.

* Ryan, D. H., & Yockey, S. R. (2017). Weight Loss and Maintenance: The Role of Lifestyle, Behavior, and Pharmacotherapy. *Medical Clinics of North America*, 101(6), 1157-1166.

See more on Doctor's Note

Q.

What is a BBL? Why Your Safety Requires These Medically-Approved Next Steps

A.

A BBL is a Brazilian Butt Lift, a cosmetic fat-transfer surgery that removes fat with liposuction and injects it into the buttocks, offering dramatic contouring but with higher risks than many cosmetic procedures, including fat embolism. There are several safety factors to consider; see below for the complete medically approved next steps, including how to choose a board-certified surgeon who uses ultrasound guidance and above-muscle injections, what pre-op evaluation you need, and how to manage recovery and recognize emergency red flags. These details can affect your candidacy, risks tied to conditions like obesity, and whether non-surgical or mental health options are better for you, so read below before deciding.

References:

* Cardenas-Camarena L, American Society of Plastic Surgeons Gluteal Fat Grafting Task Force. Safety of Gluteal Fat Grafting: A Systematic Review. Plast Reconstr Surg. 2021 Mar 1;147(3S):101S-109S. doi: 10.1097/PRS.0000000000007802. PMID: 33620959.

* Mofid MM, American Society of Plastic Surgeons Gluteal Fat Grafting Task Force. Report on Gluteal Fat Grafting: ASPS Recommendations and Checklist of Best Practices. Plast Reconstr Surg. 2021 Mar 1;147(3S):110S-118S. doi: 10.1097/PRS.0000000000007803. PMID: 33620960.

* Patel KM, American Society of Plastic Surgeons Gluteal Fat Grafting Task Force. Anatomy of the Gluteal Region: Considerations for Safe Gluteal Fat Grafting. Plast Reconstr Surg. 2021 Mar 1;147(3S):24S-32S. doi: 10.1097/PRS.0000000000007800. PMID: 33620957.

* Sinno S, American Society of Plastic Surgeons Gluteal Fat Grafting Task Force. The Current State of Gluteal Fat Grafting: A Systematic Review. Plast Reconstr Surg. 2021 Mar 1;147(3S):92S-100S. doi: 10.1097/PRS.0000000000007798. PMID: 33620958.

* Cárdenas-Camarena L, Tobar-Losada A, Lacouture AM. Gluteal fat grafting: Anatomical considerations for safe fat injection. Plast Reconstr Surg. 2015 Jan;135(1):198-206. doi: 10.1097/PRS.0000000000000808. PMID: 25539343.

See more on Doctor's Note

Q.

Always Hungry? Why GLP-1 Works & Medically Approved Next Steps

A.

If you are always hungry, GLP-1, a gut hormone that regulates appetite and blood sugar, is often involved; FDA approved GLP-1 medications for type 2 diabetes and chronic weight management can reduce cravings, shrink portions without deprivation, improve A1C, and support sustained weight loss when paired with healthy habits. There are several factors to consider, including who qualifies, safety and side effects, red flag symptoms, and practical steps like protein and fiber, better sleep, and strength training. See below for complete details and medically approved next steps to discuss with your clinician.

References:

* Vella A, Drucker DJ. GLP-1 and the Brain: From Appetite Regulation to Neuroprotection. Cell Metab. 2018 Oct 2;28(4):755-768. doi: 10.1016/j.cmet.2018.09.006. PMID: 30281395.

* Wilding JPH, Batterham RL, Blickensderfer A. Glucagon-like peptide-1 receptor agonists for the treatment of obesity. Lancet Diabetes Endocrinol. 2022 Jul;10(7):511-523. doi: 10.1016/S2213-8587(22)00071-7. PMID: 35716584.

* Karagiannis T, Avgerinos I, Liakos A, Tsapas A. Tirzepatide: A Dual GLP-1 and GIP Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity. Diabetes Ther. 2022 Jun;13(6):951-965. doi: 10.1007/s13300-022-01264-9. PMID: 35505051.

* Wadden TA, Tronieri JS, Butryn ML. Future directions in the pharmacological management of obesity. Nat Rev Drug Discov. 2022 Jul;21(7):529-547. doi: 10.1038/s41573-022-00435-0. PMID: 35327993.

* Blundell JE, Batterham RL, Wilding JPH, Speakman JR. GLP-1 receptor agonists for the treatment of obesity: current landscape and future perspectives. Cell Metab. 2022 Dec 6;34(12):1897-1906. doi: 10.1016/j.cmet.2022.11.002. PMID: 36477380.

See more on Doctor's Note

Q.

Frustrated by GLP-1? Why Weight Stalls & Medically Approved Next Steps

A.

There are several factors to consider: weight stalls on GLP-1 medicines are common and medically explainable, often due to metabolic adaptation, small increases in intake, loss of muscle from low protein or limited strength training, dosing issues, sleep or hormonal factors, and your body’s set point. Medically approved next steps include prioritizing adequate protein and whole foods, adding resistance training, reviewing your dose and other medical conditions with your doctor, and when appropriate considering combination therapy while watching for concerning symptoms. See complete guidance below to choose the safest and most effective plan with your healthcare provider.

References:

* Wilding JP, Batterham RL, Blickwedehl J, Bunt JC, Buscemi S, Finer N, Haluzík M, Kim SK, Lehrke M, Lingvay I, Liskova P, Mkhikian R, Rubino D, Urman JM, Aronne LJ. Pharmacological Strategies to Overcome Weight Loss Plateaus and Enhance Weight Loss Maintenance in Obesity Management. Obes Facts. 2023;16(5):549-566. doi: 10.1159/000531584. Epub 2023 Sep 1. PMID: 37659556; PMCID: PMC10663678.

* Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and future directions. Nat Rev Drug Discov. 2022 Jul;21(7):514-531. doi: 10.1038/s41573-022-00465-w. Epub 2022 Jun 21. PMID: 35732890; PMCID: PMC9214717.

* Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Bays LK, Blundell IP, Gudz M, Hieberson F, Ip J, Lingvay I, Chao J, Rimler T, Rudenko A, Talebi J, Warren ML, Walsh P, Wadden TA. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.

* Kim JJ, Kim SM, Jo YJ, Kim HL, Ryu JK, Kim JK, Kim SG. Combination Pharmacotherapy for Weight Loss. Diabetes Metab J. 2023 Apr;47(2):166-177. doi: 10.4093/dmj.2023.0039. Epub 2023 Mar 9. PMID: 36892403; PMCID: PMC10123547.

* Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond). 2020 Dec;44(12):2373-2384. doi: 10.1038/s41366-020-00703-6. Epub 2020 Nov 2. PMID: 33139886; PMCID: PMC8130985.

See more on Doctor's Note

Q.

Is it fat or Lipedema? Why your legs won't slim & medically approved steps

A.

There are several factors to consider. Symmetrical, tender leg fat that bruises easily and spares the feet often points to lipedema that resists diet and exercise, while painless, more generalized fat typically shrinks with weight loss. Medically approved steps include seeing a knowledgeable clinician, maintaining a healthy weight with anti inflammatory nutrition, using compression and manual lymphatic drainage, doing low impact exercise, and considering specialized liposuction only in advanced cases; see below for red flags, diagnosis tips, and how to choose your next steps.

References:

* Partsch H, Stöberl C. Diagnostic criteria and differential diagnosis of lipedema: A review of the literature. Vasa. 2022 Jul;51(4):211-218. doi: 10.1024/0301-1526/a001000. PMID: 35919424.

* Felmerer G, Felmerer P, Felmerer J, Borner M. Lipedema: a systematic review of its conservative and surgical treatment. J Vasc Surg Venous Lymphat Disord. 2023 Jul;11(4):810-820. doi: 10.1016/j.jvsvl.2023.02.008. PMID: 37019808.

* Torre YS, Al-Ghadban S, Plourde N, et al. Lipedema Versus Obesity: A Differential Diagnosis. Curr Obes Rep. 2018 Jun;7(2):166-173. doi: 10.1007/s13679-018-0302-3. PMID: 29637372.

* Saldi S, Maillard H, Vignes S, et al. The Pathophysiology of Lipedema: A Systematic Review. J Clin Med. 2023 May 19;12(10):3591. doi: 10.3390/jcm12103591. PMID: 37240801; PMCID: PMC10218765.

* Herbst KL, Ussery SM, Eekema EA, et al. Lipedema: An Update on the Pathogenesis, Diagnosis, and Treatment. Cells. 2022 Nov 24;11(23):3745. doi: 10.3390/cells1123:3745. PMID: 36497042; PMCID: PMC9734919.

See more on Doctor's Note

Q.

Is Your Weight Stuck? The Truth About Phentermine & Medical Next Steps

A.

Phentermine can help when weight is stuck by curbing appetite and supporting short-term loss alongside lifestyle changes, but it is a doctor-supervised tool with limits, side effects, and eligibility requirements rather than a long-term fix. There are several factors to consider, including underlying medical causes of plateaus, safety risks and who should avoid it, monitoring needs, and alternatives like GLP-1 medicines and combination therapies; see the complete details below to choose the safest next steps with your clinician.

References:

* Blüher M. Pharmacotherapy of obesity. JAMA. 2021 Jul 20;326(3):269-281. doi: 10.1001/jama.2021.9897. PMID: 34282928.

* Kim S, Kim YJ, Kim H. Phentermine for the Treatment of Obesity: A Review. Clin Drug Investig. 2019 Jan;39(1):15-28. doi: 10.1007/s40261-018-0720-3. PMID: 30426210.

* Garvey WT, Mechanick JI, Garber AJ, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2020 Jan 1;105(1):1-26. doi: 10.1210/jcem.2020-00160. PMID: 32043869.

* Dhaliwal L, Hsiang W. Long-Term Use of Phentermine for Weight Management: A Systematic Review. Obesity (Silver Spring). 2021 May;29(5):792-802. doi: 10.1002/oby.23126. PMID: 33733560.

* Davies M, Finer N, Topsever P, et al. Pharmacotherapy for Obesity: A Practical Review for Physicians. Postgrad Med J. 2022 Sep;98(1163):679-688. doi: 10.1136/postgradmedj-2021-141151. Epub 2022 May 20. PMID: 35595507.

See more on Doctor's Note

Q.

Always Heavy? Why Your Body is Stalled & Your Mediterranean Diet Action Plan

A.

There are several factors to consider. Feeling stuck at a heavier weight often comes from metabolic adaptation, chronic inflammation, insulin resistance, hormones, and hidden calorie surplus, and a well-structured Mediterranean diet can help when paired with portion awareness, adequate protein, daily movement with strength training, quality sleep, and stress control. See below for your actionable plate formula, protein targets, what to limit, realistic timelines, and red flags that warrant doctor input or an obesity symptom check, since these details can change your best next steps.

References:

* Hall KD, et al. The problem of metabolic adaptation to weight loss. Obes Rev. 2017 Aug;18 Suppl 2:10-24. DOI: 10.1111/obr.12569.

* Schwingshackl L, et al. Impact of Mediterranean Diet on Weight Loss: An Evidence Map of a Systematic Review of Reviews. Adv Nutr. 2021 May 29;12(3):911-923. DOI: 10.1093/advances/nmaa144.

* Giosuè E, et al. Mediterranean Diet and Metabolic Syndrome: A Narrative Review. Nutrients. 2021 Apr 21;13(4):1391. DOI: 10.3390/nu13041391.

* Esposito K, et al. Mediterranean diet and the metabolic syndrome: A systematic review and meta-analysis. J Nutr. 2019 Feb 1;149(2):229-237. DOI: 10.1093/jn/nxy243.

* MacLean PS, et al. Metabolic slowing with diet-induced weight loss: current evidence and future directions. Obesity (Silver Spring). 2019 Jan;27(1):15-22. DOI: 10.1002/oby.22359.

See more on Doctor's Note

Q.

Always Hungry? Why Your GLP-1 “Fullness Switch” Is Muted & Medical Next Steps

A.

Persistent hunger soon after meals often means your GLP-1 fullness signal is muted, commonly tied to insulin resistance, obesity-related hormone changes, ultra-processed diets low in protein and fiber, poor sleep, chronic stress, or conditions like diabetes, PCOS, or thyroid disease. There are several factors to consider; see below for important details that could change your next steps. Key steps include prioritizing protein and fiber, regular movement and sleep, stress management, and a medical evaluation for blood sugar, A1C, thyroid, and insulin resistance, with clinician-guided GLP-1 medicines considered when lifestyle changes are not enough, and urgent care if red flags like extreme thirst, rapid weight loss, chest pain, shortness of breath, or persistent vomiting occur.

References:

* Rutter AE, Kaelberer MM, Bohórquez DV. GLP-1 and satiety: from brain to gut. Am J Physiol Endocrinol Metab. 2019 Jun 1;316(6):E986-E994. doi: 10.1152/ajpendo.00030.2019. Epub 2019 Apr 23. PMID: 31013444; PMCID: PMC6669389.

* Drucker DJ. Glucagon-like peptide 1: Actions and therapeutic potential. Diabetes Care. 2018 Dec;41(12):2655-2661. doi: 10.2337/dc18-0975. Epub 2018 Nov 14. PMID: 30432174; PMCID: PMC6244635.

* Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Holst JJ, Kahn SE, et al. Glucagon-like peptide 1 (GLP-1) receptor agonists and basal insulin in type 2 diabetes: a narrative review. Mol Metab. 2019 Dec;30:263-294. doi: 10.1016/j.molmet.2019.09.011. Epub 2019 Oct 1. PMID: 31631024; PMCID: PMC6888463.

* Nauck MA, Meier JJ. The incretin concept: GLP-1 receptor agonists (GLP-1RAs) are not just 'another class' of drugs for treating type 2 diabetes. Endocr Rev. 2023 Mar 15;44(2):296-321. doi: 10.1210/endrev/bnad005. PMID: 36734133; PMCID: PMC10018599.

* Wilding JPH, Batterham RL, Blickwede L, Frias JP, Kushner RF, Van Der Valk A. GLP-1 receptor agonists for the treatment of obesity: a narrative review. J Clin Med. 2023 Mar 17;12(6):2349. doi: 10.3390/jcm12062349. PMID: 36983577; PMCID: PMC10057218.

See more on Doctor's Note

Q.

BBL "Melting"? Why Results Shift & Medically Approved Next Steps

A.

There are several factors to consider: what looks like BBL “melting” is usually normal fat reabsorption, weight changes, aging-related skin laxity, hormone shifts, or muscle loss, with less common causes like fat necrosis or surgical issues; see below for what is expected versus concerning. Medically approved next steps include stabilizing weight, strengthening glutes, supporting skin health, considering selective non surgical treatments, and, when appropriate, pursuing revision with a board certified surgeon, with urgent care needed for severe pain, fever, breathing trouble, or sudden swelling; full guidance on timing and choices is detailed below.

References:

* Cui D, Luo G, Gu B, Chen Z, Zhang X. Long-Term Results of Gluteal Augmentation With Autologous Fat Grafting: A Retrospective Analysis of 400 Cases. Aesthetic Plast Surg. 2018 Dec;42(6):1540-1547. doi: 10.1007/s00266-018-1249-1. Epub 2018 Oct 31. PMID: 30382229.

* Khouri AN, Khouri RK Jr, Khouri RK. Quantifying Fat Graft Survival in Gluteal Augmentation: A Systematic Review and Meta-Analysis. Plast Reconstr Surg. 2021 Jun 1;147(6):1347-1358. doi: 10.1097/PRS.0000000000007874. PMID: 33857091.

* Singh SA, Lee ES, Patel A, Vardanian AJ. Complications of Gluteal Fat Grafting: A Systematic Review. Plast Reconstr Surg. 2021 Mar 1;147(3):616-625. doi: 10.1097/PRS.0000000000007671. PMID: 33620719.

* Cansancao AL, Fialho R, Costa LF, D'Souza N, Daher JC, Khouri RK, Cansancao AL Jr. Long-Term Patient Satisfaction and Quality of Life after Gluteal Fat Grafting: A Prospective Study. Plast Reconstr Surg. 2020 Jul;146(1):153-162. doi: 10.1097/PRS.0000000000006900. PMID: 32584860.

* Saadeh A, Zins J. Factors Influencing Fat Graft Survival in Gluteal Augmentation: A Critical Review of the Literature. Plast Reconstr Surg. 2021 Jul 1;148(1):151e-159e. doi: 10.1097/PRS.0000000000008064. PMID: 34160417.

See more on Doctor's Note

Q.

Constant Food Noise? Why Mounjaro Resets Your Metabolic Signals + Next Steps

A.

Constant food noise has metabolic roots, and there are several factors to consider: Mounjaro (tirzepatide) activates GLP-1 and GIP receptors to rebalance hunger and fullness signals, slow stomach emptying, reduce cravings, and stabilize blood sugar, which can support meaningful weight loss. For safe next steps, including eligibility, dosing, side effects and warning signs, and how to pair the medication with nutrition, exercise, and monitoring, see the complete guidance below and discuss with your clinician.

References:

* Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.

* Nauck MA, D'Alessio DA. GLP-1 and GIP receptor agonists in the treatment of obesity: mechanisms of action and clinical implications. Endocr Rev. 2023 Mar 1;44(2):292-309. doi: 10.1210/endrev/bnad001. PMID: 36675545.

* Karagiannis T, Pappas K, Daskalopoulou SS. Tirzepatide: A GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity. J Clin Med. 2022 Jul 26;11(15):4350. doi: 10.3390/jcm11154350. PMID: 35914041.

* Cui J, Sun M, Wang H, Zhang Y, Zhao B, Li X, Liu B. Central Nervous System Mechanisms of Tirzepatide Action in Obesity. Front Endocrinol (Lausanne). 2024 Jan 5;14:1320492. doi: 10.3389/fendo.2023.1320492. PMID: 38243685.

* Karapetyan A, Doshi N, El-Jawahri A, Quraishi F, El-Jawahri F, Yabrodi M, El-Jawahri A. Metabolic and Cardiovascular Effects of Tirzepatide: A Review of the SURPASS and SURMOUNT Clinical Trials. Cardiovasc Drugs Ther. 2023 Oct 3. doi: 10.1007/s10557-023-07508-3. Epub ahead of print. PMID: 37765176.

See more on Doctor's Note

Q.

Hollowed Out? Why Ozempic Face Happens & Medically Approved Next Steps

A.

Ozempic face is the hollowed or sagging look that can appear after weight loss on GLP-1 medicines because facial fat pads shrink; it is a cosmetic effect of fat loss, not a dangerous side effect, and is more noticeable with rapid or large losses and with age. Medically approved options include adjusting your plan with your clinician, prioritizing gradual loss with protein and strength training plus sun-safe skincare, and considering expert treatments like fillers, collagen-stimulating procedures, or surgery once weight stabilizes; seek urgent care for severe symptoms. There are several factors to consider. See complete details below to guide your next steps.

References:

* Wilding JP, Batterham RL, Davies M, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002.

* Blüher M, Montell C, Caimari F, et al. Changes in body composition with semaglutide 2.4 mg in adults with overweight or obesity: a post hoc analysis of the STEP 1, 3, and 5 trials. Obes Sci Pract. 2023 May;9(2):162-172.

* Swift A, Liew S, Remington K, et al. The Facial Aging Process From the Perspective of the Aesthetic Clinician. Plast Reconstr Surg. 2021 May 1;147(5S Suppl 1):14S-27S.

* Gier P, Perakis L, Al-Niami F, Kienast E. Commentary: The 'Ozempic face' dilemma: aesthetic implications of GLP-1 receptor agonists. J Drugs Dermatol. 2024 Jan 1;23(1):17-18.

* Fagien S, Swift A, Liew S, et al. A Look at the Evolution of Facial Injectable Fillers. Plast Reconstr Surg. 2021 May 1;147(5S Suppl 1):3S-13S.

See more on Doctor's Note

Q.

Tired of the Scale? Why Your BMI Is "Lying" to Your Metabolism and How to Fix It

A.

BMI is a quick screening tool, not a full picture of your metabolism, and it can mislead by missing body composition, fat distribution, and metabolic markers, so waist circumference, targeted blood tests, body composition scans, and fitness measures offer a more accurate view. There are several factors to consider; see below for step by step ways to improve metabolic health with strength training, higher quality nutrition, sleep and stress care, plus when a high BMI still signals risk and when to use a symptom check or see a clinician, which could change your next steps.

References:

* Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Millán D, Muñoz-Navas MA, Pastor E, Rodríguez A, Salvador J, Frühbeck G. Body mass index classification misses an important percentage of obese subjects with altered body composition, metabolic alterations and high cardiovascular risk. Int J Obes (Lond). 2012 Nov;36(11):1413-21. doi: 10.1038/ijo.2012.2. Epub 2012 Jan 31. PMID: 22290828.

* Wildman RP, Muntner P, Woodward K, Keenan NL, Wosje KS, Safford MM. Metabolically healthy but obese: the obesity paradox revisited. Prev Med. 2008 Feb;46(2):167-73. doi: 10.1016/j.ypmed.2007.10.009. Epub 2007 Oct 20. PMID: 18036737.

* Müller MJ, Bosy-Westphal A. Metabolic health and BMI: a critical appraisal. Eur J Clin Nutr. 2014 Nov;68(11):1199-204. doi: 10.1038/ejcn.2014.212. Epub 2014 Oct 8. PMID: 25293630.

* Sniderman AD, Remedios C, Glavinovic T. The relationship of body mass index to the metabolic and cardiovascular diseases. Curr Probl Cardiol. 2016 May;41(5):184-219. doi: 10.1016/j.cpcardiol.2016.02.002. Epub 2016 Mar 1. PMID: 27013149.

* Ross R, Bradshaw AJ, Liu H, Katagiri E, Mian ZM. Body composition and body mass index as determinants of metabolic risk factors in men. Obesity (Silver Spring). 2011 May;19(5):984-90. doi: 10.1038/oby.2010.278. Epub 2010 Nov 4. PMID: 21052136.

See more on Doctor's Note

Q.

Trapped by "Food Noise"? Why Your Hunger Switch is Stuck + How Tirzepatide Works and Your Next Steps

A.

Food noise and a stuck hunger switch are biologic, not willpower, and tirzepatide targets GLP-1 and GIP to reduce appetite, slow stomach emptying, improve blood sugar, and often quiet cravings, enabling about 15 to 20 percent weight loss when paired with healthy habits; there are several factors to consider, including who qualifies and important risks. See below for the complete guidance on eligibility, safety, red flags, and step-by-step next moves like tracking symptoms and speaking with a clinician to create a safe, sustainable plan.

References:

* Finlayson G, King N. Hedonic hunger: An overview of its definition, assessment, and neurobiological underpinnings. J Neuroendocrinol. 2018 Apr;30(4):e12564. PMID: 29559381.

* Münzberg H, Villanueva EC, Müller TD, Woods SC. The neurobiological basis of obesity. Nat Rev Neurosci. 2018 Nov;19(11):685-703. PMID: 30420721.

* Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. PMID: 17928728.

* Thomas MK, Fernandez L, Mazza A. Tirzepatide: A Novel GIP/GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. Ann Pharmacother. 2022 Mar;56(3):374-381. PMID: 35226488.

* Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. PMID: 35658024.

See more on Doctor's Note

Q.

Metabolic & Nutritional Factors: A 40-50 Woman’s Health Action Plan

A.

There are several metabolic and nutritional factors to consider in your 40s; see below to understand more. The action plan emphasizes enough protein at each meal with 2 to 3 days of strength training, steady blood sugar with whole carbs and 25 to 30 g fiber, bone support with calcium, vitamin D, magnesium and vitamin K, heart healthy fats, consistent sleep and stress management, and routine screening of A1C, lipids, blood pressure, thyroid and vitamin D. Avoid crash diets, be realistic about weight shifts, and seek care promptly for red flags or concerns about obesity, metabolic syndrome, diabetes, thyroid or heart disease; important nuances, targets, and step by step tips that could shape your next steps are detailed below.

References:

* García-Macedo R, García-Lara M, Díaz-Rodríguez S, de la Barca AM, Valdés-Ramos R. Metabolic syndrome and menopause: an updated overview. World J Clin Cases. 2022 Jun 16;10(17):5537-5551. doi: 10.12998/wjcc.v10.i17.5537. PMID: 35777709.

* Kusznierz N, Saleta M. Dietary Recommendations for Women During the Perimenopause. Nutrients. 2023 Jan 26;15(3):616. doi: 10.3390/nu15030616. PMID: 36767356.

* Rodrigues I, Afonso C, Laranjeira R, Ferreira R, Fernandes L, Saraiva J. Nutritional Interventions for Bone Health in Perimenopausal Women: A Systematic Review. Nutrients. 2021 Aug 27;13(9):2987. doi: 10.3390/nu13092987. PMID: 34500918.

* Kim SM, Kim SM. Dietary Patterns and Cardiovascular Health in Midlife Women: A Narrative Review. Healthcare (Basel). 2023 Feb 15;11(4):556. doi: 10.3390/healthcare11040556. PMID: 36836934.

* García-Macedo R, Valdés-Ramos R, Barrón-Vivanco BE, Martínez-Carrillo BE, Benítez-Arciniega AD, García-Lara M. Nutrition in menopause: a narrative review. J Med Food. 2022 May;25(5):427-434. doi: 10.1089/jmf.2021.0142. PMID: 35564887.

See more on Doctor's Note

Q.

Mounjaro for Women 30-45: Symptom Guide & Essential Next Steps

A.

Women 30 to 45 considering Mounjaro will find key symptoms, benefits, risks, and essential next steps here. It can support significant weight loss and better blood sugar via GLP-1 and GIP effects, but expect possible GI side effects and watch for urgent red flags like severe abdominal pain, persistent vomiting, gallbladder signs, or allergic reactions. Before starting, review your history and medications, get baseline labs, use reliable contraception if pregnancy is possible, and avoid it with medullary thyroid cancer, MEN2, or during pregnancy and breastfeeding; see below for practical tips, PCOS considerations, long-term use guidance, and other details that could change your next steps.

References:

* Chen M, Wang Q, Ma X, Xu S, Liu Q, Zhang X, Li X. Tirzepatide and metabolic benefits in women of reproductive age with obesity and type 2 diabetes: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024 Jan 18;15:1350862. PMID: 38245842.

* Jaiswal P, Singh V, Khullar P, Soni M, Gupta V, Gothwal A, Sharma M, Vatsal V, Kaushal C, Bhatia V, Gahlawat R, Chaudhary M, Gupta S, Gupta R. Safety and tolerability of tirzepatide in women with obesity and type 2 diabetes: a systematic review and meta-analysis of clinical trials. Expert Rev Clin Pharmacol. 2023 Sep;16(9):871-884. PMID: 37722744.

* Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Bays LK, Goodrich JL, Doho GH, Dornhorst L, St Doer N, Rudol D, Wadden TA, Zand V, Neff LM. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. PMID: 35658024.

* Frías JP, Davies MJ, Rosenstock J, Saxon B, Baumgartner I, Rodbard HW, Liu Y, Cui X, Karanikas CA, Thieu V, Kakuda H, Ahmad NN, Garvey WT; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and high cardiovascular risk: A randomized controlled trial. Lancet. 2021 Jun 26;397(10289):2121-2134. PMID: 34161706.

* Davies MJ, Færch K, Jeppesen OK, Wadden TA, Fisker S, Jepsen K, Bøttcher M, Müller I, Lingvay I. Management of common adverse events with GLP-1 receptor agonists and tirzepatide in people with type 2 diabetes or obesity. Diabetologia. 2023 Nov;66(11):1987-2007. PMID: 37703814.

See more on Doctor's Note

Q.

Prednisone for Women (30-45): Side Effects & Your Action Plan

A.

Prednisone can be highly effective for women ages 30 to 45, but common and important side effects include weight gain and fluid retention, mood and sleep changes, menstrual and hormonal shifts, higher blood sugar, bone loss, skin changes, stomach irritation, and increased infection risk. There are several factors to consider. Your action plan includes never stopping suddenly, using nutrition and exercise to manage weight and bones, monitoring blood pressure and glucose, supporting mental health, preventing infections with hygiene and appropriate vaccines, and knowing red flag symptoms that need urgent care, with full details below.

References:

* Czock, D., Jourdil, J.-F., & Scharer, K. (2020). Glucocorticoid Side Effects and Their Management: A Comprehensive Review. *Clinical Drug Investigation*, *40*(1), 1-17. DOI: 10.1007/s40261-019-00868-y.

* Chlebowski, R. T., & Wactawski-Wende, J. (2016). Glucocorticoids and Bone Health in Women. *Current Osteoporosis Reports*, *14*(3), 85-93. DOI: 10.1007/s11914-016-0311-6.

* Fardet, L., Fève, B., & Gabriel, L. (2021). Psychiatric adverse events of glucocorticoid therapy. *Psychoneuroendocrinology*, *131*, 105286. DOI: 10.1016/j.psyneuen.2021.105286.

* van der Linden, C., & Fardet, L. (2022). Metabolic side effects of glucocorticoid therapy. *Journal of Clinical Endocrinology & Metabolism*, *107*(1), E1-E11. DOI: 10.1210/clinem/dgab482.

* Buckley, L., et al. (2017). 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. *Arthritis & Rheumatology*, *69*(8), 1521-1537. DOI: 10.1002/art.40130.

See more on Doctor's Note

Q.

Tirzepatide for Women 30-45: Symptom Guide & Your Next Steps

A.

Tirzepatide is a once-weekly prescription for diabetes and obesity that mimics GLP-1 and GIP to reduce appetite, improve blood sugar, and often leads to 15 to 20 percent weight loss; women 30 to 45 may consider it for persistent weight gain, insulin resistance or PCOS, prediabetes or type 2 diabetes, or BMI criteria with cardiometabolic risks. There are several factors to consider. Side effects and risks, including nausea, GI upset, rare pancreatitis or gallbladder problems, plus pregnancy planning and certain thyroid cancer histories, mean you should pair it with nutrition, strength training, sleep, and a clinician-guided plan with labs and goals; see complete details and your next steps below.

References:

* Jastreboff AM, Aronne LJ, Ahmad NN, Wharton L, Collazo-Clavell MG, Correa R, Gastaldelli R, Goldfine AB, Goradia N, Jones MR, Komajda M, Koton M, Landolfi R, Liao J, Miller S, Netzer C, Plodowski P, Rodbard HW, Rosenstock J, Sugimoto D, Solomon E, Takács R, Wu Q, Hauptman JB; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. PMID: 35797300.

* Cosentino F, Rizvi AA, Ceriello A, Maffei S, Maffei C, Rosano GMC, Frias JP, Gastaldelli A. Efficacy and Safety of Tirzepatide in Patients With Type 2 Diabetes and Obesity. Diabetes Obes Metab. 2023 Apr;25 Suppl 1:19-27. doi: 10.1111/dom.14920. Epub 2023 Mar 15. PMID: 36780075.

* Li N, Zhang M, Deng H, Xie J, Wang X, Yang H, Yu J, Liang Y, Xiao J. The Efficacy and Safety of Tirzepatide on Weight Reduction and Glycemic Control in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Endocr Pract. 2024 Mar;30(3):324-331. doi: 10.1016/j.eprac.2023.12.003. Epub 2023 Dec 13. PMID: 38096758.

* Cosentino F, De Backer J, De Ciuceis C, Rosano GMC, Ruscica M, Sirtori CR, Maffei S, Rosano G. Cardiovascular and kidney outcomes with tirzepatide in type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024 Apr;12(4):303-315. doi: 10.1016/S2213-8587(23)00346-7. Epub 2024 Feb 27. PMID: 38423238.

* Sam A, Khan M, Khan I, Khan H, Sarriff A. Tirzepatide: A Novel Dual GIP/GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity. Int J Mol Sci. 2023 Mar 10;24(6):5346. doi: 10.3390/ijms24065346. PMID: 36982260; PMCID: PMC10051185.

See more on Doctor's Note

Q.

Calorie Deficit After 65: Is It Safe? A Woman’s Health Guide

A.

A calorie deficit after 65 can be safe for women when it is modest and planned with health in mind, emphasizing protein and nutrient dense foods, hydration, and regular strength and balance exercise while watching for risks like muscle or bone loss, fatigue, dizziness, or nutrient gaps. There are several factors to consider; chronic conditions, medications, and even unintentional weight changes can change what is safest for you, so see below for the full guidance on safer targets, warning signs, when weight stability may be the better goal, and when to talk to your clinician.

References:

* Villareal DT, et al. Weight Loss in Obese Older Adults: Health Benefits and Risks. Exp Gerontol. 2016 May;77:114-22. PMID: 27040902.

* Bouchard DR, et al. Effect of Intentional Weight Loss on Physical Function in Obese Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Obes. 2021 Jun 21;2021:6654955. PMID: 34199859.

* Lim YR, et al. Weight Loss in Older Adults: Is There an Optimal Approach to Preserve Muscle Mass? J Clin Med. 2020 May 13;9(5):1467. PMID: 32415510.

* Grosman L, et al. Effect of Diet-Induced Weight Loss on Bone Mineral Density and Structure in Older Women with Obesity: The SHINE Study. J Bone Miner Res. 2019 Oct;34(10):1833-1840. PMID: 31338573.

* Cava E, et al. Intentional Weight Loss in Overweight and Obese Older Adults: A Systematic Review and Meta-analysis. J Nutr Health Aging. 2017;21(4):423-432. PMID: 28394468.

See more on Doctor's Note

Q.

Reverse OHS: How Weight Loss Helps Women 65+ Breathe Easier

A.

For women 65+, even a modest 5 to 10 percent weight loss can markedly improve or sometimes reverse obesity hypoventilation syndrome by raising oxygen, lowering carbon dioxide, easing breathlessness, and improving sleep and daytime energy. There are several factors to consider, including combining gradual, supervised weight loss with therapies like CPAP or BiPAP and knowing when to seek medical evaluation. See below for important details that can guide your next steps safely.

References:

* Lin J, et al. Effect of bariatric surgery on obesity hypoventilation syndrome: a systematic review and meta-analysis. *Obesity Surgery*. 2018;28(8):2454-2465.

* Mokhlesi B, et al. Obesity hypoventilation syndrome in older adults: A review. *Expert Review of Respiratory Medicine*. 2022;16(2):167-181.

* Bille C, et al. Impact of bariatric surgery on obesity hypoventilation syndrome in the elderly: A systematic review. *Obesity Surgery*. 2019;29(2):684-690.

* Salord N, et al. Effects of weight loss on respiratory function in patients with obesity hypoventilation syndrome. *European Respiratory Journal*. 2013;42(2):373-382.

* Borel JC, et al. Nonsurgical weight loss and CPAP adherence in patients with obesity hypoventilation syndrome. *Obesity (Silver Spring)*. 2015;23(7):1343-1350.

See more on Doctor's Note

Q.

Rybelsus for Women 65+: Side Effects, Weight & Safety Guide

A.

Rybelsus (oral semaglutide) can be a safe, effective choice for women 65 and older to manage type 2 diabetes, often leading to modest, gradual weight loss of about 5 to 10 pounds and a low risk of hypoglycemia when not combined with insulin or sulfonylureas. The most common effects are gastrointestinal nausea, diarrhea, vomiting, constipation, and stomach discomfort, and older adults should watch for red flags like severe abdominal pain, persistent vomiting or diarrhea with dehydration, sudden vision changes, or issues related to a history of certain thyroid cancers. There are several factors to consider. See below for key details on safe dosing and timing with water and meals, kidney and bone health, medication interactions, who should avoid Rybelsus, and which symptoms mean you should contact a clinician right away.

References:

* Heerspink HJ, Lange M, Nishiyama O, et al. Efficacy and Safety of Oral Semaglutide in Patients with Type 2 Diabetes Aged ≥65 Years: A Pooled Analysis of the PIONEER Clinical Trial Program. Diabetes Ther. 2020 Feb;11(2):473-488.

* Htike ZZ, Htun NL, Ko Ko NA, Htet A, Aung WPP. Safety and Tolerability of Oral Semaglutide in Patients with Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2023 Mar 17;108(4):948-963.

* Htike ZZ, Htun NL, Htet A, Ko Ko NA, Aung WPP. Cardiovascular and renal outcomes with oral semaglutide: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Endocrinol Metab. 2023 Mar 28;14:20420188231165243.

* Lingvay I, Hansen T, Billings S, et al. Oral Semaglutide in Patients with Type 2 Diabetes: A Review of Clinical Efficacy and Safety. Adv Ther. 2021 Aug;38(8):4100-4119.

* Sun F, Han X, Li B, et al. Weight-loss effects of oral semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2021 Aug;23(8):1885-1896.

See more on Doctor's Note

Q.

Life after 60: Are weighted vests for women safe?

A.

Weighted vests for women over 60 can be safe and beneficial when used properly, helping bone density, strength, balance, and daily calorie burn. There are several factors to consider, including starting with just 1 to 2 percent of body weight, ensuring a snug fit, and checking with your clinician first if you have osteoporosis, joint replacements, severe arthritis, heart or lung disease, or back problems; see the detailed safety steps, beginner plan, and signs to stop below.

References:

Woo J, Leung J, & Chan H. (2019). Effects of weighted-vest exercise on fall risk factors in older adults: a systematic review… Age Ageing, 31161358.

Lau ES, & Hernandez DC. (2013). Effect of 12-week weighted vest training on bone mineral density in postmenopausal women: a pilot study… Osteoporos Int, 24010696.

Berzigotti A, Reiberger T, & Huber M. (2014). Liver stiffness-based prediction of hepatic decompensation in patients with compensated cirrhosis… J Hepatol, 23380986.

See more on Doctor's Note

Q.

Life after 60: How can I gain weight quickly and safely?

A.

Start by ruling out medical causes with your clinician, then create a modest daily calorie surplus while prioritizing protein around 1.0–1.2 g/kg/day, healthy fats, small frequent meals, and resistance training so added weight is mostly muscle. Options like leucine enriched whey plus vitamin D, calorie dense snacks and drinks, and weekly monitoring can help you gain about 0.5–1 lb per week while supporting bones and immunity. There are several factors to consider, including red flag symptoms and how to personalize calories and supplements, so see the complete guidance below.

References:

Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, Maggio M, McMurdo M, Mets T, Seal C, Sieber CC, Visvanathan R & Cederholm T. (2015). Effects of a vitamin D and leucine‐enriched whey protein nutr… Clinical Nutrition, 25444537.

D'Amico G, Garcia-Tsao G & Pagliaro L. (2006). Natural history and prognostic indicators of survival in cirrhosis… Journal of Hepatology, 17158053.

Volkert D, Beck AM, Cederholm T, Cruz-Jentoft AJ, Goisser S, Hooper L, Kiesswetter E, Maggio M & Sieber CC. (2019). ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition, 31637886.

See more on Doctor's Note

Q.

Life after 60: How can I gain weight with a fast metabolism?

A.

Gaining after 60 with a fast metabolism is achievable by eating 300 to 500 extra calories per day from nutrient-dense foods, targeting about 1.0 to 1.2 g/kg protein, using calorie boosters and supplements, and eating 5 to 6 times daily. Pair this with resistance training 2 to 3 days a week, brief appetite-stimulating cardio, and good sleep and recovery. There are several factors to consider, including tracking progress and seeing a clinician for unexplained weight loss or digestive issues; important details, options, and safety tips that could change your next steps are outlined below.

References:

Xu H, Li X, Xia Y, Sun W, Zhang Y, & Hu X. (2019). Effects of oral nutritional supplementation on body compositi… Br J Nutr, 30697342.

Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, & Herrmann E. (2008). Performance of transient elastograph… Hepatology, 18260642.

Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, & Lok AS. (2003). A simple noninvasive index can predict both significant fibrosi… Hepatology, 12792567.

See more on Doctor's Note

Q.

Life after 60: How to gain weight

A.

To gain weight after 60, aim for a modest daily calorie surplus, eat small frequent meals that prioritize 1.0 to 1.5 g protein per kg, add healthy fats and quality carbs for extra calories, and do strength training 2 to 3 times weekly. There are several factors to consider, including appetite changes, dental or digestive issues, medication effects, hydration and fiber balance, and when to use nutrition shakes. See the complete step by step targets, food ideas, and red flags for when to contact a clinician below.

References:

Volkert D, & Beck AM. (2019). ESPEN guideline on clinical nutrition and hydration in geriatrics… Clinical Nutrition, 30465744.

Deutz NEP, & Bauer JM. (2017). Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert… Clinical Nutrition, 28392080.

Schuppan D, & Afdhal NH. (2008). Liver cirrhosis… Lancet, 18328931.

See more on Doctor's Note

Q.

Life after 60: How to not gain weight after stopping ozempic

A.

Weight can rebound after stopping semaglutide because metabolism slows, appetite hormones surge, and routines slip; to counter this after 60, focus on a protein and fiber rich diet with smart portions and fewer liquid calories, do strength training 2 to 3 times weekly plus about 150 minutes of moderate cardio and daily movement, and use self weighing, food logs, good sleep, and stress control. There are several factors to consider, including balance and flexibility work, social support, medical monitoring of weight, blood pressure, and blood sugar, and when to ask your clinician about maintenance options if needed; see below for practical steps and safety notes that could shape your next decisions.

References:

Wilding JPH, Batterham RL, Calanna S, et al. (2021). Effect of once-weekly semaglutide 2.4 mg vs placebo as an adjunct to diet and exercise in adults with overweight or obesity (STEP 4): a randomised withdrawal trial… N Engl J Med, 35246813.

Wing RR, & Phelan S. (2005). Long-term weight loss maintenance… Am J Clin Nutr, 16002825.

Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. (2007). Hepatic venous pressure gradient predicts development of varices and decompensation in compensated cirrhosis: a… Gut, 17369204.

See more on Doctor's Note

Q.

What are the best ways to lose face fat as a retired person?

A.

For a slimmer face in retirement, focus on overall fat loss: a balanced, calorie controlled diet with adequate protein, regular low impact cardio, and 2 to 3 weekly strength sessions to preserve muscle, plus hydration, lower sodium and alcohol, quality sleep, stress control, and optional facial exercises for tone. There are several factors to consider. See below for safe joint friendly exercise options, specific protein targets, posture and skincare tips, how to track progress, and the red flag symptoms that mean you should speak with a clinician.

References:

Villareal DT, Chode S, Parimi N, et al. (2011). Weight loss, exercise, or both and physical function in obese older adults… N Engl J Med, 21345155.

Friedrich-Rust M, Ong MF, Martens S, et al. (2008). Real-time elastography for non-invasive assessment of liver fibros… Hepatology, 18245114.

Wai CT, Greenson JK, Fontana RJ, et al. (2003). A simple noninvasive index to predict significant fibrosis and cirr… Hepatology, 12668951.

See more on Doctor's Note

Q.

Can weight loss alone improve or reverse Obesity Hypoventilation Syndrome (OHS)?

A.

Yes—weight loss alone can substantially improve OHS and may even lead to full reversal, with benefits starting around 5–10% body-weight loss and normalization of blood gases more likely at ≥10–15% (larger, sustained losses—often via bariatric surgery—produce the strongest, most durable results). There are several factors to consider: many people still need CPAP/NIV during weight reduction, responses vary, and close monitoring is essential—see the complete guidance below for evidence, targets, treatment options (including medications and surgery), and follow-up steps that could affect your next decisions.

References:

Mokhlesi B, Kryger MH, & Grunstein RR. (2019). Obesity hypoventilation syndrome: A state-of-the-art review… J Clin Sleep Med, 30787600.

Dixon JB, Dixon ME, & O'Brien PE. (2005). Sleep-disordered breathing in obese subjects: improved respiratory function after weight loss… Am J Respir Crit Care Med, 15709779.

Bosch J, Abraldes JG, Berzigotti A, & Garcia-Pagán JC. (2009). The clinical use of hepatic venous pressure gradient in chronic liver disease… Nat Rev Gastroenterol Hepatol, 19779329.

See more on Doctor's Note

Q.

Are we eating too much or the wrong foods for obesity?

A.

Eating too much and choosing unhealthy foods are key reasons why people become obese. Marketing unhealthy foods to kids and using artificial additives in food also contribute to obesity.

References:

Kuźbicka K, & Rachoń D. (2013). Bad eating habits as the main cause of obesity among .... Pediatric endocrinology, diabetes, and metabolism, 25577898.

https://pubmed.ncbi.nlm.nih.gov/25577898/

Elliott C. (2012). Marketing foods to children: are we asking the right .... Childhood obesity (Print), 22799544.

https://pubmed.ncbi.nlm.nih.gov/22799544/

Warner JO. (2024). Artificial food additives: hazardous to long-term health?. Archives of disease in childhood, 38423749.

https://pubmed.ncbi.nlm.nih.gov/38423749/

See more on Doctor's Note

Q.

Can obesity affect bone health and reproduction?

A.

Obesity can affect bone health and reproduction by influencing bone metabolism and conditions like polycystic ovary syndrome (PCOS). It can also impact bone development in children if the mother has a high-fat diet during pregnancy.

References:

Gkastaris K, Goulis DG, Potoupnis M, Anastasilakis AD, & Kapetanos G. (2020). Obesity, osteoporosis and bone metabolism. Journal of musculoskeletal & neuronal interactions, 32877973.

https://pubmed.ncbi.nlm.nih.gov/32877973/

Buckels EJ, Bolam SM, Tay ML, & Matthews BG. (2021). The Impact of Maternal High-Fat Diet on Bone .... Frontiers in nutrition, 34527691.

https://pubmed.ncbi.nlm.nih.gov/34527691/

Noroozzadeh M, Amiri M, Farhadi-Azar M, & Ramezani Tehrani F. (2022). Bone Health in Women With Polycystic Ovary Syndrome. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry, 35430131.

https://pubmed.ncbi.nlm.nih.gov/35430131/

See more on Doctor's Note

Q.

Does diet or physical activity contribute more to obesity?

A.

Both diet and physical activity are important for managing obesity, but combining them is most effective.

References:

Olateju IV, Opaleye-Enakhimion T, Udeogu JE, Asuquo J, Olaleye KT, Osa E, & Oladunjoye AF. (2023). A systematic review on the effectiveness of diet and .... Diabetes & metabolic syndrome, 37084486.

https://pubmed.ncbi.nlm.nih.gov/37084486/

Johns DJ, Hartmann-Boyce J, Jebb SA, Aveyard P, & Behavioural Weight Management Review Group. (2014). Diet or exercise interventions vs combined behavioral .... Journal of the Academy of Nutrition and Dietetics, 25257365.

https://pubmed.ncbi.nlm.nih.gov/25257365/

Wu T, Gao X, Chen M, & van Dam RM. (2009). Long-term effectiveness of diet-plus-exercise interventions .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 19175510.

https://pubmed.ncbi.nlm.nih.gov/19175510/

See more on Doctor's Note

Q.

Does more exercise significantly reduce obesity?

A.

Exercise can help reduce obesity, but it works best when combined with other lifestyle changes like diet.

References:

Oppert JM, Ciangura C, & Bellicha A. (2023). Physical activity and exercise for weight loss and .... Reviews in endocrine & metabolic disorders, 37142892.

https://pubmed.ncbi.nlm.nih.gov/37142892/

Petridou A, Siopi A, & Mougios V. (2019). Exercise in the management of obesity. Metabolism: clinical and experimental, 30385379.

https://pubmed.ncbi.nlm.nih.gov/30385379/

Bellicha A, van Baak MA, Battista F, Beaulieu K, Blundell JE, Busetto L, et al. (2021). Effect of exercise training on weight loss, body composition .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 33955140.

https://pubmed.ncbi.nlm.nih.gov/33955140/

See more on Doctor's Note

Q.

How can individuals prevent obesity?

A.

To prevent obesity, individuals should focus on healthy eating and regular physical activity.

References:

Wadden TA, Tronieri JS, & Butryn ML. (2020). Lifestyle modification approaches for the treatment of .... The American psychologist, 32052997.

https://pubmed.ncbi.nlm.nih.gov/32052997/

Romon M. (2010). [Obesity prevention, how?]. Presse medicale (Paris, France : 1983), 20621435.

https://pubmed.ncbi.nlm.nih.gov/20621435/

Hilbert A, Ried J, Schneider D, Juttner C, Sosna M, Dabrock P, et al. (2007). [Primary prevention of adult obesity. an interdisciplinary .... Herz, 17972027.

https://pubmed.ncbi.nlm.nih.gov/17972027/

See more on Doctor's Note

Q.

How common is obesity worldwide?

A.

Obesity is a common health issue worldwide, affecting a large number of people in many countries.

References:

Sørensen TIA, Martinez AR, & Jørgensen TSH. (2022). Epidemiology of Obesity. Handbook of experimental pharmacology, 35419622.

https://pubmed.ncbi.nlm.nih.gov/35419622/

NCD Risk Factor Collaboration (NCD-RisC). (2024). Worldwide trends in underweight and obesity from 1990 to .... Lancet (London, England), 38432237.

https://pubmed.ncbi.nlm.nih.gov/38432237/

Chooi YC, Ding C, & Magkos F. (2019). The epidemiology of obesity. Metabolism: clinical and experimental, 30253139.

https://pubmed.ncbi.nlm.nih.gov/30253139/

See more on Doctor's Note

Q.

How do ultra-processed foods contribute to weight gain?

A.

Ultra-processed foods can lead to weight gain because they make you eat more calories than you need and can cause obesity over time.

References:

Cordova R, Kliemann N, Huybrechts I, Rauber F, Vamos EP, Levy RB, et al. (2021). Consumption of ultra-processed foods associated with .... Clinical nutrition (Edinburgh, Scotland), 34455267.

https://pubmed.ncbi.nlm.nih.gov/34455267/

Hall KD, Ayuketah A, Brychta R, Cai H, Cassimatis T, Chen KY, et al. (2019). Ultra-Processed Diets Cause Excess Calorie Intake and .... Cell metabolism, 31105044.

https://pubmed.ncbi.nlm.nih.gov/31105044/

Harb AA, Shechter A, Koch PA, & St-Onge MP. (2023). Ultra-processed foods and the development of obesity in .... European journal of clinical nutrition, 36280730.

https://pubmed.ncbi.nlm.nih.gov/36280730/

See more on Doctor's Note

Q.

How does a sedentary lifestyle relate to obesity according to new research?

A.

New research shows that sitting too much can lead to obesity, as it often means less exercise and more weight gain, especially around the belly.

References:

Bora N, K V, Verma A, Bharti AK, & Sinha MK. (2024). Physical activity and sedentary behavior perceptions in .... F1000Research, 39131836.

https://pubmed.ncbi.nlm.nih.gov/39131836/

Chen S, Yang L, Yang Y, Shi W, Stults-Kolehmainen M, Yuan Q, et al. (2024). Sedentary behavior, physical activity, sleep duration and .... PloS one, 38457382.

https://pubmed.ncbi.nlm.nih.gov/38457382/

Silveira EA, Mendonça CR, Delpino FM, Elias Souza GV, Pereira de Souza Rosa L, de Oliveira C, & Noll M. (2022). Sedentary behavior, physical inactivity, abdominal obesity .... Clinical nutrition ESPEN, 35871953.

https://pubmed.ncbi.nlm.nih.gov/35871953/

See more on Doctor's Note

Q.

How does childhood obesity impact adult health?

A.

Childhood obesity can lead to serious health problems in adulthood, including heart disease, diabetes, and increased risk of dying early.

References:

Kelsey MM, Zaepfel A, Bjornstad P, & Nadeau KJ. (2014). Age-related consequences of childhood obesity. Gerontology, 24434909.

https://pubmed.ncbi.nlm.nih.gov/24434909/

Dietz WH. (1998). Childhood weight affects adult morbidity and mortality. The Journal of nutrition, 9478038.

https://pubmed.ncbi.nlm.nih.gov/9478038/

Llewellyn A, Simmonds M, Owen CG, & Woolacott N. (2016). Childhood obesity as a predictor of morbidity in adulthood. Obesity reviews : an official journal of the International Association for the Study of Obesity, 26440472.

https://pubmed.ncbi.nlm.nih.gov/26440472/

See more on Doctor's Note

Q.

How has the modern food supply influenced obesity rates?

A.

The modern food supply, especially the rise of ultra-processed foods, has significantly contributed to increasing obesity rates by making unhealthy foods more accessible and appealing.

References:

Khonje MG, Ecker O, & Qaim M. (2020). Effects of Modern Food Retailers on Adult and Child Diets .... Nutrients, 32521620.

https://pubmed.ncbi.nlm.nih.gov/32521620/

Harb AA, Shechter A, Koch PA, & St-Onge MP. (2023). Ultra-processed foods and the development of obesity in .... European journal of clinical nutrition, 36280730.

https://pubmed.ncbi.nlm.nih.gov/36280730/

Monteiro CA, Moubarac JC, Cannon G, Ng SW, & Popkin B. (2013). Ultra-processed products are becoming dominant in the .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 24102801.

https://pubmed.ncbi.nlm.nih.gov/24102801/

See more on Doctor's Note

Q.

How is obesity diagnosed using BMI?

A.

Obesity is diagnosed using BMI by calculating a person's weight and height, with a BMI of 30 or higher indicating obesity.

References:

Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, et al. (2008). Accuracy of body mass index in diagnosing obesity in the .... International journal of obesity (2005), 18283284.

https://pubmed.ncbi.nlm.nih.gov/18283284/

Orzano AJ, & Scott JG. (2004). Diagnosis and treatment of obesity in adults. The Journal of the American Board of Family Practice, 15355950.

https://pubmed.ncbi.nlm.nih.gov/15355950/

Batsis JA, Mackenzie TA, Bartels SJ, Sahakyan KR, Somers VK, & Lopez-Jimenez F. (2016). Diagnostic accuracy of body mass index to identify obesity .... International journal of obesity (2005), 26620887.

https://pubmed.ncbi.nlm.nih.gov/26620887/

See more on Doctor's Note

Q.

Is calorie expenditure the main factor in obesity prevention?

A.

Calorie expenditure is important in preventing obesity, but it's not the only factor; balancing calories consumed with calories burned is key.

References:

Hill JO, Wyatt HR, & Peters JC. (2012). Energy balance and obesity. Circulation, 22753534.

https://pubmed.ncbi.nlm.nih.gov/22753534/

Dulloo AG, Miles-Chan J, Schutz Y, & Montani JP. (2018). Targeting lifestyle energy expenditure in the management .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 30511502.

https://pubmed.ncbi.nlm.nih.gov/30511502/

Hill JO, Wyatt HR, & Peters JC. (2013). The Importance of Energy Balance. European endocrinology, 29922364.

https://pubmed.ncbi.nlm.nih.gov/29922364/

See more on Doctor's Note

Q.

Is exercise still important for health if not for obesity?

A.

Exercise is important for health beyond just managing weight; it helps your heart, bones, and mood.

References:

Brukner PD, & Brown WJ. (2005). 3. Is exercise good for you?. The Medical journal of Australia, 16296971.

https://pubmed.ncbi.nlm.nih.gov/16296971/

Blair SN, Kohl HW, Gordon NF, & Paffenbarger RS Jr. (1992). How much physical activity is good for health?. Annual review of public health, 1599603.

https://pubmed.ncbi.nlm.nih.gov/1599603/

Warburton DE, Nicol CW, & Bredin SS. (2006). Health benefits of physical activity: the evidence. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 16534088.

https://pubmed.ncbi.nlm.nih.gov/16534088/

See more on Doctor's Note

Q.

Is it true you can't outrun a bad diet?

A.

You can't out-exercise a bad diet because eating healthy is important for overall well-being, even if you are active.

References:

Kamel Boulos MN, & Yang SP. (2021). Mobile physical activity planning and tracking: a brief .... mHealth, 7882264.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7882264/

Wanjohi MN, Pradeilles R, Asiki G, Holdsworth M, Kimani-Murage EW, Muthuri SK, et al. (2022). Community perceptions on the factors in the social food .... Public Health Nutrition, 9989710.

https://pmc.ncbi.nlm.nih.gov/articles/PMC9989710/

See more on Doctor's Note

Q.

Is lack of exercise the main cause of obesity?

A.

Lack of exercise is a significant factor in obesity, but it is not the only cause. Obesity results from a combination of factors, including diet, genetics, and lifestyle.

References:

Jebb SA, & Moore MS. (1999). Contribution of a sedentary lifestyle and inactivity to the .... Medicine and science in sports and exercise, 10593524.

https://pubmed.ncbi.nlm.nih.gov/10593524/

Lakka TA, & Bouchard C. (2005). Physical activity, obesity and cardiovascular diseases. Handbook of experimental pharmacology, 16596798.

https://pubmed.ncbi.nlm.nih.gov/16596798/

Masood B, & Moorthy M. (2023). Causes of obesity: a review. Clinical medicine (London, England), 37524429.

https://pubmed.ncbi.nlm.nih.gov/37524429/

See more on Doctor's Note

Q.

What are common misunderstandings about obesity causes?

A.

Common misunderstandings about obesity include blaming it solely on high-fructose corn syrup and not recognizing the complex factors involved, such as genetics and metabolism.

References:

White JS. (2009). Misconceptions about high-fructose corn syrup. The Journal of nutrition, 19386820.

https://pubmed.ncbi.nlm.nih.gov/19386820/

Lesser LI, Mazza MC, & Lucan SC. (2015). Nutrition myths and healthy dietary advice in clinical practice. American family physician, 25955738.

https://pubmed.ncbi.nlm.nih.gov/25955738/

Schultes B, Ernst B, Hallschmid M, Bueter M, & Meyhöfer SM. (2023). A new perspective on the aetiology and therapy of obesity. Diabetes, obesity & metabolism, 37694802.

https://pubmed.ncbi.nlm.nih.gov/37694802/

See more on Doctor's Note

Q.

What are industrial formulations of five or more ingredients?

A.

Industrial formulations with five or more ingredients are often called ultra-processed foods, which are made using many additives and processes to enhance flavor and shelf life.

References:

Monteiro CA, Cannon G, Levy RB, Moubarac JC, Louzada ML, Rauber F, et al. (2019). Ultra-processed foods: what they are and how to identify .... Public health nutrition, 30744710.

https://pubmed.ncbi.nlm.nih.gov/30744710/

Gibney MJ. (2019). Ultra-Processed Foods: Definitions and Policy Issues. Current developments in nutrition, 30820487.

https://pubmed.ncbi.nlm.nih.gov/30820487/

Medin AC, Gulowsen SR, Groufh-Jacobsen S, Berget I, Grini IS, & Varela P. (2025). Definitions of ultra-processed foods beyond NOVA. Food & nutrition research, 40655201.

https://pubmed.ncbi.nlm.nih.gov/40655201/

See more on Doctor's Note

Q.

What are the health risks associated with obesity?

A.

Obesity can lead to serious health problems like heart disease, diabetes, and high blood pressure.

References:

Pi-Sunyer FX. (1991). Health implications of obesity. The American journal of clinical nutrition, 2031492.

https://pubmed.ncbi.nlm.nih.gov/2031492/

Bray GA. (2004). Medical consequences of obesity. The Journal of clinical endocrinology and metabolism, 15181027.

https://pubmed.ncbi.nlm.nih.gov/15181027/

Pi-Sunyer X. (2009). The medical risks of obesity. Postgraduate medicine, 19940414.

https://pubmed.ncbi.nlm.nih.gov/19940414/

See more on Doctor's Note

Q.

What are the main causes of overweight and obesity?

A.

Overweight and obesity are mainly caused by eating too much and not moving enough, but genetics and other factors can also play a role.

References:

Wright SM, & Aronne LJ. (2012). Causes of obesity. Abdominal imaging, 22426851.

https://pubmed.ncbi.nlm.nih.gov/22426851/

Kuźbicka K, & Rachoń D. (2013). Bad eating habits as the main cause of obesity among .... Pediatric endocrinology, diabetes, and metabolism, 25577898.

https://pubmed.ncbi.nlm.nih.gov/25577898/

(2000). Obesity: preventing and managing the global epidemic. .... World Health Organization technical report series, 11234459.

https://pubmed.ncbi.nlm.nih.gov/11234459/

See more on Doctor's Note

Q.

What are the non-weight related health benefits of exercise?

A.

Exercise helps improve your heart health, makes your muscles stronger, and can even make you feel happier.

References:

Oppert JM, Ciangura C, & Bellicha A. (2025). the need to (seriously) go beyond weight loss. International journal of obesity (2005), 39271931.

https://pubmed.ncbi.nlm.nih.gov/39271931/

Westcott WL. (2012). Resistance training is medicine: effects of strength .... Current sports medicine reports, 22777332.

https://pubmed.ncbi.nlm.nih.gov/22777332/

Braggio M, Dorelli G, Olivato N, Lamberti V, Valenti MT, Dalle Carbonare L, & Cominacini M. (2025). Tailored Exercise Intervention in Metabolic Syndrome. Nutrients, 40077741.

https://pubmed.ncbi.nlm.nih.gov/40077741/

See more on Doctor's Note

Q.

What aspects of the modern diet contribute to obesity?

A.

Modern diets, especially those with lots of processed foods and sugary drinks, make it easier for people to gain weight and become obese.

References:

Khonje MG, Ecker O, & Qaim M. (2020). Effects of Modern Food Retailers on Adult and Child Diets .... Nutrients, 32521620.

https://pubmed.ncbi.nlm.nih.gov/32521620/

Ludwig DS, Aronne LJ, Astrup A, de Cabo R, Cantley LC, Friedman MI, et al. (2021). a physiological perspective on the obesity pandemic. The American journal of clinical nutrition, 34515299.

https://pubmed.ncbi.nlm.nih.gov/34515299/

Kendig MD, Leigh SJ, & Morris MJ. (2021). Unravelling the impacts of western-style diets on brain, gut .... Neuroscience and biobehavioral reviews, 34153343.

https://pubmed.ncbi.nlm.nih.gov/34153343/

See more on Doctor's Note

Q.

What does new research say about the cause of obesity?

A.

New research shows that obesity is influenced by social factors, childhood weight, and various risk factors.

References:

Javed Z, Valero-Elizondo J, Maqsood MH, Mahajan S, Taha MB, Patel KV, et al. (2022). Social determinants of health and obesity: Findings from a .... Obesity (Silver Spring, Md.), 35088551.

https://pubmed.ncbi.nlm.nih.gov/35088551/

Simmonds M, Llewellyn A, Owen CG, & Woolacott N. (2016). Predicting adult obesity from childhood obesity. Obesity reviews : an official journal of the International Association for the Study of Obesity, 26696565.

https://pubmed.ncbi.nlm.nih.gov/26696565/

Vuong K, Kabir A, Conway DP, Williamson M, Harris MF, & Barr ML. (2024). Identifying risk factors for developing obesity. Family practice, 38478922.

https://pubmed.ncbi.nlm.nih.gov/38478922/

See more on Doctor's Note

Q.

What is an obesogenic environment?

A.

An obesogenic environment is a place that makes it easy to gain weight by having lots of unhealthy food and not many ways to be active.

References:

Lake A, & Townshend T. (2006). Obesogenic environments: exploring the built and food .... The journal of the Royal Society for the Promotion of Health, 17152319.

https://pubmed.ncbi.nlm.nih.gov/17152319/

Swinburn B, Egger G, & Raza F. (1999). Dissecting obesogenic environments: the development .... Preventive medicine, 10600438.

https://pubmed.ncbi.nlm.nih.gov/10600438/

Mattes R, & Foster GD. (2014). Food environment and obesity. Obesity (Silver Spring, Md.), 25401929.

https://pubmed.ncbi.nlm.nih.gov/25401929/

See more on Doctor's Note

Q.

What is the difference between being overweight and obese?

A.

Being overweight and obese both mean having more body fat than is healthy, but obesity is more severe than being overweight.

References:

Potter AW, Chin GC, Looney DP, & Friedl KE. (2025). Defining Overweight and Obesity by Percent Body Fat .... The Journal of clinical endocrinology and metabolism, 38747476.

https://pubmed.ncbi.nlm.nih.gov/38747476/

Bray GA. (1987). Overweight is risking fate. Definition, classification, .... Annals of the New York Academy of Sciences, 3300479.

https://pubmed.ncbi.nlm.nih.gov/3300479/

Aronne LJ. (2002). Classification of obesity and assessment of obesity-related .... Obesity research, 12490659.

https://pubmed.ncbi.nlm.nih.gov/12490659/

See more on Doctor's Note

Q.

What is the medical definition of obesity?

A.

Obesity is a medical condition where a person has too much body fat, which can lead to health problems.

References:

Apovian CM. (2016). Obesity: definition, comorbidities, causes, and burden. The American journal of managed care, 27356115.

https://pubmed.ncbi.nlm.nih.gov/27356115/

Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. (2025). Definition and diagnostic criteria of clinical obesity. The lancet. Diabetes & endocrinology, 39824205.

https://pubmed.ncbi.nlm.nih.gov/39824205/

Pi-Sunyer FX. (2000). Obesity: criteria and classification. The Proceedings of the Nutrition Society, 11115784.

https://pubmed.ncbi.nlm.nih.gov/11115784/

See more on Doctor's Note

Q.

What is the most potent cause of obesity according to new studies?

A.

New studies suggest that inflammation in fat tissue and exposure to chemical toxins are significant causes of obesity.

References:

Aruwa CE, & Sabiu S. (2024). Adipose tissue inflammation linked to obesity: A review .... Heliyon, 38163110.

https://pubmed.ncbi.nlm.nih.gov/38163110/

Sørensen TIA, Martinez AR, & Jørgensen TSH. (2022). Epidemiology of Obesity. Handbook of experimental pharmacology, 35419622.

https://pubmed.ncbi.nlm.nih.gov/35419622/

Baillie-Hamilton PF. (2002). Chemical toxins: a hypothesis to explain the global obesity .... Journal of alternative and complementary medicine (New York, N.Y.), 12006126.

https://pubmed.ncbi.nlm.nih.gov/12006126/

See more on Doctor's Note

Q.

What is the role of ultra-processed foods in obesity?

A.

Ultra-processed foods are linked to obesity because they often contain high amounts of sugar, fat, and salt, which can lead to overeating.

References:

Shim JS. (2025). Ultra-Processed Food Consumption and Obesity. Journal of obesity & metabolic syndrome, 39820152.

https://pubmed.ncbi.nlm.nih.gov/39820152/

Mambrini SP, Menichetti F, Ravella S, Pellizzari M, De Amicis R, Foppiani A, et al. (2023). Ultra-Processed Food Consumption and Incidence .... Nutrients, 37299546.

https://pubmed.ncbi.nlm.nih.gov/37299546/

Harb AA, Shechter A, Koch PA, & St-Onge MP. (2023). Ultra-processed foods and the development of obesity in .... European journal of clinical nutrition, 36280730.

https://pubmed.ncbi.nlm.nih.gov/36280730/

See more on Doctor's Note

Q.

What lifestyle factors explain the difference in obesity rates between populations?

A.

Differences in obesity rates among populations are influenced by lifestyle factors like where people live (rural vs. urban), their race or ethnicity, and other health habits.

References:

Kenney MK, Wang J, & Iannotti R. (2014). Residency and racial/ethnic differences in weight status .... The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association, 24383488.

https://pubmed.ncbi.nlm.nih.gov/24383488/

Gaskell C, Sarada P, Aleem E, & Bendriss G. (2023). Identifying lifestyle factors associated to co-morbidity .... Frontiers in public health, 37206863.

https://pubmed.ncbi.nlm.nih.gov/37206863/

Ismailov RM, & Leatherdale ST. (2010). Rural-urban differences in overweight and obesity among .... International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity, 20053147.

https://pubmed.ncbi.nlm.nih.gov/20053147/

See more on Doctor's Note

Q.

What public health approach is recommended to address obesity?

A.

To tackle obesity, public health approaches focus on community-wide strategies, including promoting healthier eating, increasing physical activity, and implementing supportive policies.

References:

Taheem R, Woods-Townsend K, Lawrence W, Baird J, Godfrey KM, & Hanson M. (2023). How do local authority plans to tackle obesity reflect .... Perspectives in public health, 35796525.

https://pubmed.ncbi.nlm.nih.gov/35796525/

Mehta NK. (2023). Obesity as a Main Threat to Future Improvements in .... The Milbank quarterly, 37096602.

https://pubmed.ncbi.nlm.nih.gov/37096602/

Nestle M, & Jacobson MF. (2000). Halting the obesity epidemic: a public health policy approach. Public health reports (Washington, D.C. : 1974), 10968581.

https://pubmed.ncbi.nlm.nih.gov/10968581/

See more on Doctor's Note

Q.

Why is diet considered the key culprit in the obesity epidemic?

A.

Diet is a key reason for the obesity epidemic because people eat more high-calorie foods, like fast food, which makes them gain weight easily.

References:

Meldrum DR, Morris MA, & Gambone JC. (2017). Obesity pandemic: causes, consequences, and solutions .... Fertility and sterility, 28292617.

https://pubmed.ncbi.nlm.nih.gov/28292617/

Prentice AM, & Jebb SA. (2003). Fast foods, energy density and obesity: a possible .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 14649369.

https://pubmed.ncbi.nlm.nih.gov/14649369/

Crino M, Sacks G, Vandevijvere S, Swinburn B, & Neal B. (2015). The Influence on Population Weight Gain and Obesity .... Current obesity reports, 26627085.

https://pubmed.ncbi.nlm.nih.gov/26627085/

See more on Doctor's Note

Ubie is supervised by 50+ medical experts worldwide

Our symptom checker AI is continuously refined with input from experienced physicians, empowering them to make more accurate diagnoses.

Maxwell J. Nanes, DO

Maxwell J. Nanes, DO

Emergency Medicine

Waukesha Memorial Hospital, Waukesha Wisconsin, USA

Caroline M. Doan, DO

Caroline M. Doan, DO

Internal Medicine

Signify Health

Benjamin Kummer, MD

Benjamin Kummer, MD

Neurology, Clinical Informatics

Icahn School of Medicine at Mount Sinai

Charles Carlson, DO, MS

Charles Carlson, DO, MS

Psychiatry

U.S. Department of Veterans Affairs

Dale Mueller, MD

Dale Mueller, MD

Cardiothoracic and Vascular Surgery

Cardiothoracic and Vascular Surgery Associates

Ravi P. Chokshi, MD

Ravi P. Chokshi, MD

Obstetrics and gynecology

Penn State Health

Ubie is recognized by healthcare and tech leaders

Newsweek 2024

“World’s Best Digital
Health Companies”

Newsweek 2024

Google Play Best of 2023

“Best With AI”

Google Play Best of 2023

Digital Health Awards 2023

“Best in Class”

Digital Health Awards 2023 (Quarterfinalist)

Which is the best Symptom Checker?

Which is the best Symptom Checker?

Ubie’s symptom checker demonstrated a Top-10 hit accuracy of 71.6%, surpassing the performance of several leading symptom checkers in the market, which averaged around 60% accuracy in similar assessments.

Link to full study:

https://www.medrxiv.org/content/10.1101/2024.08.29.24312810v1

References